### PHILIPPINE BIDDING DOCUMENTS

# Procurement of GOODS

Government of the Republic of the Philippines

**CITY GOVERNMENT OF NAGA** 

Name of Project/Contract:

Supply and Delivery of Drugs and Medicines

**Project/Contract Reference Number: 2024-005** 

Sixth Edition July 2020

#### **Preface**

These Philippine Bidding Documents (PBDs) for the procurement of Goods through Competitive Bidding have been prepared by the Government of the Philippines for use by any branch, constitutional commission or office, agency, department, bureau, office, or instrumentality of the Government of the Philippines, National Government Agencies, including Government-Owned and/or Controlled Corporations, Government Financing Institutions, State Universities and Colleges, and Local Government Unit. The procedures and practices presented in this document have been developed through broad experience, and are for mandatory use in projects that are financed in whole or in part by the Government of the Philippines or any foreign government/foreign or international financing institution in accordance with the provisions of the 2016 revised Implementing Rules and Regulations of Republic Act No. 9184.

The Bidding Documents shall clearly and adequately define, among others: (i) the objectives, scope, and expected outputs and/or results of the proposed contract or Framework Agreement, as the case may be; (ii) the eligibility requirements of Bidders; (iii) the expected contract or Framework Agreement duration, the estimated quantity in the case of procurement of goods, delivery schedule and/or time frame; and (iv) the obligations, duties, and/or functions of the winning bidder.

Care should be taken to check the relevance of the provisions of the PBDs against the requirements of the specific Goods to be procured. If duplication of a subject is inevitable in other sections of the document prepared by the Procuring Entity, care must be exercised to avoid contradictions between clauses dealing with the same matter.

Moreover, each section is prepared with notes intended only as information for the Procuring Entity or the person drafting the Bidding Documents. They shall not be included in the final documents. The following general directions should be observed when using the documents:

- a. All the documents listed in the Table of Contents are normally required for the procurement of Goods. However, they should be adapted as necessary to the circumstances of the particular Procurement Project.
- b. Specific details, such as the "name of the Procuring Entity" and "address for bid submission," should be furnished in the Instructions to Bidders, Bid Data Sheet, and Special Conditions of Contract. The final documents should contain neither blank spaces nor options.
- c. This Preface and the footnotes or notes in italics included in the Invitation to Bid, Bid Data Sheet, General Conditions of Contract, Special Conditions of Contract, Schedule of Requirements, and Specifications are not part of the text of the final document, although they contain instructions that the Procuring Entity should strictly follow.

- d. The cover should be modified as required to identify the Bidding Documents as to the Procurement Project, Project Identification Number, and Procuring Entity, in addition to the date of issue.
- e. Modifications for specific Procurement Project details should be provided in the Special Conditions of Contract as amendments to the Conditions of Contract. For easy completion, whenever reference has to be made to specific clauses in the Bid Data Sheet or Special Conditions of Contract, these terms shall be printed in bold typeface on Sections I (Instructions to Bidders) and III (General Conditions of Contract), respectively.
- f. For guidelines on the use of Bidding Forms and the procurement of Foreign-Assisted Projects, these will be covered by a separate issuance of the Government Procurement Policy Board.

### **Table of Contents**

| Glossar | y of Acronyms, Terms, and Abbreviations                            | 4  |
|---------|--|----|
| Section | I. Invitation to Bid   | 7  |
| Section | II. Instructions to Bidders  | 7  |
| 1.      | Scope of Bid   | 14 |
| 2.      | Funding Information.   | 14 |
| 3.      | Bidding Requirements   | 14 |
| 4.      | Corrupt, Fraudulent, Collusive, and Coercive Practices             | 14 |
| 5.      | Eligible Bidders   | 15 |
| 6.      | Origin of Goods  | 16 |
| 7.      | Subcontracts   | 16 |
| 8.      | Pre-Bid Conference   | 16 |
| 9.      | Clarification and Amendment of Bidding Documents                   | 16 |
| 10.     | Documents comprising the Bid: Eligibility and Technical Components | 16 |
| 11.     | Documents comprising the Bid: Financial Component                  | 17 |
| 12.     | Bid Prices   | 17 |
| 13.     | Bid and Payment Currencies   | 18 |
| 14.     | Bid Security   | 18 |
| 15.     | Sealing and Marking of Bids  | 18 |
| 16.     | Deadline for Submission of Bids                                    | 18 |
| 17.     | Opening and Preliminary Examination of Bids                        | 19 |
| 18.     | Domestic Preference  | 19 |
| 19.     | Detailed Evaluation and Comparison of Bids                         | 19 |
| 20.     | Post-Qualification   | 20 |
| 21.     | Signing of the Contract  | 20 |
| Section | III. Bid Data Sheet  | 21 |
| Section | IV. General Conditions of Contract                                 | 22 |
| 1.      | Scope of Contract  | 22 |
| 2.      | Advance Payment and Terms of Payment                               | 22 |
| 3.      | Performance Security   | 22 |
| 4.      | Inspection and Tests   | 22 |
| 5.      | Warranty   | 23 |
| 6.      | Liability of the Supplier  | 23 |
| Section | V. Special Conditions of Contract                                  | 24 |
| Section | VI. Schedule of Requirements                                       | 27 |
| Section | VII. Technical Specifications                                      | 27 |
| Section | VIII. Checklist of Technical and Financial Documents               | 33 |

# Glossary of Acronyms, Terms, and Abbreviations

**ABC** –Approved Budget for the Contract.

**BAC** – Bids and Awards Committee.

**Bid** – A signed offer or proposal to undertake a contract submitted by a bidder in response to and in consonance with the requirements of the bidding documents. Also referred to as Proposal and Tender. (2016 revised IRR, Section 5[c])

**Bidder** – Refers to a contractor, manufacturer, supplier, distributor and/or consultant who submits a bid in response to the requirements of the Bidding Documents. (2016 revised IRR, Section 5[d])

**Bidding Documents** – The documents issued by the Procuring Entity as the bases for bids, furnishing all information necessary for a prospective bidder to prepare a bid for the Goods, Infrastructure Projects, and/or Consulting Services required by the Procuring Entity. (2016 revised IRR, Section 5[e])

**BIR** – Bureau of Internal Revenue.

**BSP** – Bangko Sentral ng Pilipinas.

Consulting Services – Refer to services for Infrastructure Projects and other types of projects or activities of the GOP requiring adequate external technical and professional expertise that are beyond the capability and/or capacity of the GOP to undertake such as, but not limited to: (i) advisory and review services; (ii) pre-investment or feasibility studies; (iii) design; (iv) construction supervision; (v) management and related services; and (vi) other technical services or special studies. (2016 revised IRR, Section 5[i])

**CDA** - Cooperative Development Authority.

Contract – Refers to the agreement entered into between the Procuring Entity and the Supplier or Manufacturer or Distributor or Service Provider for procurement of Goods and Services; Contractor for Procurement of Infrastructure Projects; or Consultant or Consulting Firm for Procurement of Consulting Services; as the case may be, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.

**CIF** – Cost Insurance and Freight.

**CIP** – Carriage and Insurance Paid.

**CPI** – Consumer Price Index.

**DDP** – Refers to the quoted price of the Goods, which means "delivered duty paid."

**DTI** – Department of Trade and Industry.

**EXW** – Ex works.

**FCA** – "Free Carrier" shipping point.

**FOB** – "Free on Board" shipping point.

**Foreign-funded Procurement or Foreign-Assisted Project**—Refers to procurement whose funding source is from a foreign government, foreign or international financing institution as specified in the Treaty or International or Executive Agreement. (2016 revised IRR, Section 5[b]).

Framework Agreement – Refers to a written agreement between a procuring entity and a supplier or service provider that identifies the terms and conditions, under which specific purchases, otherwise known as "Call-Offs," are made for the duration of the agreement. It is in the nature of an option contract between the procuring entity and the bidder(s) granting the procuring entity the option to either place an order for any of the goods or services identified in the Framework Agreement List or not buy at all, within a minimum period of one (1) year to a maximum period of three (3) years. (GPPB Resolution No. 27-2019)

**GFI** – Government Financial Institution.

**GOCC** –Government-owned and/or –controlled corporation.

Goods – Refer to all items, supplies, materials and general support services, except Consulting Services and Infrastructure Projects, which may be needed in the transaction of public businesses or in the pursuit of any government undertaking, project or activity, whether in the nature of equipment, furniture, stationery, materials for construction, or personal property of any kind, including non-personal or contractual services such as the repair and maintenance of equipment and furniture, as well as trucking, hauling, janitorial, security, and related or analogous services, as well as procurement of materials and supplies provided by the Procuring Entity for such services. The term "related" or "analogous services" shall include, but is not limited to, lease or purchase of office space, media advertisements, health maintenance services, and other services essential to the operation of the Procuring Entity. (2016 revised IRR, Section 5[r])

**GOP** – Government of the Philippines.

**GPPB** –Government Procurement Policy Board.

**INCOTERMS** – International Commercial Terms.

**Infrastructure Projects** – Include the construction, improvement, rehabilitation, demolition, repair, restoration or maintenance of roads and bridges, railways, airports, seaports, communication facilities, civil works components of information technology projects, irrigation, flood control and drainage, water supply, sanitation, sewerage and

solid waste management systems, shore protection, energy/power and electrification facilities, national buildings, school buildings, hospital buildings, and other related construction projects of the government. Also referred to as civil works or works. (2016 revised IRR, Section 5[u])

LGUs - Local Government Units.

**NFCC** – Net Financial Contracting Capacity.

**NGA** – National Government Agency.

**PhilGEPS -** Philippine Government Electronic Procurement System.

**Procurement Project** – refers to a specific or identified procurement covering goods, infrastructure project or consulting services. A Procurement Project shall be described, detailed, and scheduled in the Project Procurement Management Plan prepared by the agency which shall be consolidated in the procuring entity's Annual Procurement Plan. (GPPB Circular No. 06-2019 dated 17 July 2019)

**PSA** – Philippine Statistics Authority.

**SEC** – Securities and Exchange Commission.

**SLCC** – Single Largest Completed Contract.

**Supplier** – refers to a citizen, or any corporate body or commercial company duly organized and registered under the laws where it is established, habitually established in business and engaged in the manufacture or sale of the merchandise or performance of the general services covered by his bid. (Item 3.8 of GPPB Resolution No. 13-2019, dated 23 May 2019). Supplier as used in these Bidding Documents may likewise refer to a distributor, manufacturer, contractor, or consultant.

**UN** – United Nations.

### Section I. Invitation to Bid

# INVITATION TO BID FOR THE SUPPLY AND DELIVERY OF DRUGS AND MEDICINES

1. The City Government of Naga, through the Naga City General Hospital (NCGH) Drugs and Medicines account, intends to apply the sum of Three Million Three Hundred Eighty-Five Thousand Five Hundred Forty-Nine (P 3,385,549.00) Pesos, being the Approved Budget for the Contract (ABC), to payments under the contract for the Supply and Delivery of Drugs and Medicines for use in the NCGH Operations, with Project/Contract Reference Number: 2024-005. Bids received in excess of the ABC shall be automatically rejected at bid opening.

| Item<br>No. | Qty. U | Unit | Items   | Approved Budget for the Contract (ABC) |
|-------------|--------|------|---|--|
| 1           | 1,000  | Tab  | Acetylcysteine 600 mg effervescent tab : ORAL   | 25,500.00                              |
| 2           | 10     | Tab  | Adenosine 3mg/ml 2ml Amp/Vial   | 2,500.00                               |
| 3           | 500    | Tab  | Allopurinol 100 mg tab : ORAL   | 1,500.00                               |
| 4           | 10     | Tab  | Aminophylline (theophylline ethylenediamine) 25 mg/ml 10 ml amp IV: INJ                       | 350.00                                 |
| 5           | 100    | Amp  | Amiodarone 200 mg tab (as hydrochloride): ORAL  | 1,600.00                               |
| 6           | 10     | Tab  | Amiodarone 50 mg / ml, 3 ml amp (IV) (as hydrochloride): INJ                                  | 4,200.00                               |
| 7           | 20,000 | Tab  | Amlodipine 5 mg tab (as besilate): ORAL   | 50,000.00                              |
| 8           | 10,000 | Bot  | Amlodipine 10 mg tab (as besilate) : ORAL   | 35,000.00                              |
| 9           | 3,000  | Tab  | Amoxicillin 500 mg cap (as trihydrate): ORAL  | 7,500.00                               |
| 10          | 144    | Amp  | Amoxicillin 100 mg / ml granules / powder for drops (suspension) 10 ml (as trihydrate) : ORAL | 2,880.00                               |
| 11          | 144    | Tab  | Amoxicillin 250 mg / 5 ml granules / powder for susp 60 ml (as trihydrate) : ORAL             | 4,320.00                               |
| 12          | 30     | Tab  | Ampicillin 500 mg vl (im,iv) (as sodium salt): INJ  | 750.00                                 |
| 13          | 200    | Cap  | Ampicillin 500mg Sulbactam250mg (as sodium salt) / vl (im,iv) : INJ                           | 40,000.00                              |
| 14          | 300    | Cap  | Anti Rabies Serum (equine) 200 iu ml / 5 ml vl (im) : INJ                                     | 435,000.00                             |
| 15          | 2,500  | Amp  | Anti Tetanus Serum (equine) 1500 iu /0.7 ml 0.7 ml vl / amp (im) : INJ                        | 225,000.00                             |
| 16          | 3,000  | Tab  | Ascorbic Acid (Vit C) 500 mg tab: ORAL  | 4,500.00                               |
| 17          | 144    | Bot  | Ascorbic Acid (Vit C) 100 mg / ml drops 15ml : ORAL   | 4,320.00                               |
| 18          | 144    | Bot  | Ascorbic Acid (Vit C) 100 mg / 5 ml syr 60 ml : ORAL  | 5,040.00                               |

| 19 | 3,000 | Tab  | Atorvastatin Calcium 20mg Tab   | 15,000.00 |
|----|-------|------|---|-----------|
| 20 | 50    | Amp  | Atracurium (as Besilate) 10mg/mL  | 10,000.00 |
|    |       | r    | (2.5mL/5mL) (IV)  | 10,000.00 |
| 21 | 10    | Amp  | Atropine 1 mg / ml 1 ml amp (im,iv) (as sulfate): INJ   | 700.00    |
| 22 | 3,000 | Tab  | Azithromycin 500 mg tab (as base / as dihydrate) : ORAL   | 36,000.00 |
| 23 | 100   | Via1 | BCG Vaccine (freeze-dried powder, 100micrograms/0.1 mL, 1mL)  | 53,500.00 |
| 24 | 150   | Tab  | Betahistine (as<br>Hydrochloride/dihydrochloride) 16mg,<br>Tablet   | 1,800.00  |
| 25 | 300   | Tab  | Betahistine (as<br>Hydrochloride/dihydrochloride) 24mg<br>Tablet  | 7,500.00  |
| 26 | 30    | Bot  | Biphasic Isophane human insulin 70 / 30 (recombinant DNA) 70 %isophane susp. 30 % sol. insulin in 100 iu /ml 10mL vl (IM,SC): INJ | 11,550.00 |
| 27 | 100   | Tab  | Bisacodyl 5 mg tab : ORAL   | 350.00    |
| 28 | 30    | Supp | Bisacodyl 5 mg (children) supp : RECTAL   | 600.00    |
| 29 | 30    | Supp | Bisacodyl 10 mg (adult) supp : RECTAL   | 1,800.00  |
| 30 | 100   | Amp  | Bupivacaine Hydrochloride solution for spinal injection, 0.5% Heavy, 4 ml amp : Local Anesthetic                                  | 9,000.00  |
| 31 | 1,000 | Tab  | Butamirate 50 mg MR/SRtab (as citrate) : ORAL   | 13,500.00 |
| 32 | 70    | Amp  | Butorphanol (as Tartrate) 2mg/mL Soln for INJ (IM/IV)   | 37,100.00 |
| 33 | 20    | Amp  | Calcium Gluconate 10 %, 10 ml amp / vl (IV): INJ  | 400.00    |
| 34 | 10    | Amp  | Carboprost250mcg/ml amp/vial  | 2,500.00  |
| 35 | 144   | Bot  | Cefalexin 100 mg / ml granules / powder for drops 15 ml (as monohydrate) : ORAL   | 3,600.00  |
| 36 | 200   | Tab  | Cefixime 200 mg Tab: ORAL   | 3,000.00  |
| 37 | 144   | Bot  | Cefixime (as trihydrate ) 20 mg/mL , 10mL drops   | 20,160.00 |
| 38 | 144   | Bot  | Cefixime (as trihydrate ) 100 mg/5mL , 60mL suspension  | 21,600.00 |
| 39 | 30    | Via1 | Ceftazidime 500 mg vl (im,iv) ( as pentahydrate ): INJ  | 4,500.00  |
| 40 | 30    | Via1 | Ceftazidime 1 g vl (im,iv) ( as pentahydrate ) : INJ  | 1,500.00  |
| 41 | 200   | Vial | Ceftriaxone 1 g vl 10 ml diluent (iv) (as disodium sodium salt) : INJ   | 70,400.00 |
| 42 | 2,000 | Tab  | Cefuroxime 500 mg tab ( as axetil ): ORAL   | 88,000.00 |
| 43 | 50    | Vial | Cefuroxime 750 mg vl (im,iv) (as sodium salt): INJ  | 4,500.00  |
| 44 | 288   | Bot  | Cefuroxime 250 mg / 5 ml granules for susp, 50 ml : ORAL  | 60,480.00 |
| 45 | 144   | Bot  | Cetirizine 2.5 mg / ml syrup (oral drops ) 10mL   | 10,080.00 |
| 46 | 500   | Tab  | Ciprofloxacin 500mg Tab   | 9,000.00  |
| 47 | 500   | Tab  | Clarithromycin 500mg tab : ORAL   | 7,500.00  |
| 48 | 144   | Bot  | Clarithromycin 125 mg / 5 ml<br>granules/powder for susp, 25 ml : ORAL  | 24,480.00 |
| 49 | 400   | Tab  | Clonidine 75mcg Tab   | 2,400.00  |
| 50 | 1,500 | Tab  | Clopidogrel 75 mg tab : ORAL  | 7,500.00  |

|         |       | ·    | · •   |           |
|---------|-------|------|---|-----------|
| 51      | 144   | Bot  | Cloxacillin 250 mg / 5 ml powder for syr / susp 60 ml (as sodium salt) : ORAL   | 5,184.00  |
| 52      | 288   | Bot  | Co Amoxiclav Susp 200mg/28.5mg/5ml 70ml   | 43,200.00 |
| 53      | 288   | Bot  | Co Amoxiclav 457mg/5mL, 70 mL   | 57,600.00 |
|         |       |      | Cotrimoxazole (sulfamethoxazole +   |           |
| 54      | 72    | Bot  | trimethoprim) 200 mg + 40 mg / 5 ml susp 60 ml : ORAL   | 2,016.00  |
| 55      | 10    | Amp  | Diclofenac 25 mg / ml, 3 ml amp ( IM, IV ) ( as sodium salt ) : INJ   | 220.00    |
| 56      | 100   | Tab  | Digoxin 250 mcg (.25 mg) tab : ORAL   | 700.00    |
| 57      | 20    | Amp  | Digoxin 250 mcg / ml 2 ml amp (im,iv): INJ  | 3,800.00  |
| 58      | 10    | Via1 | Dobutamine 50 mg / ml ,5mL , 0.5m l solution for injection vial : INJ   | 2,200.00  |
| 59      | 100   | Tab  | Domperidone 10 mg tab : ORAL  | 1,200.00  |
| 60      | 30    | INJ  | Enoxaparin 40 mg / 0.4 ml prefilled syringe (SC) (as sodium) :INJ   | 13,710.00 |
| 61      | 50    | Amp  | Epinephrine (Adrenaline) 1 mg / ml 1 ml amp (im,sc) (as hydrochloride) : INJ  | 1,500.00  |
| 62      | 300   | Tab  | Erythromycin 500 mg tab (as stearate): ORAL   | 1,350.00  |
| 63      | 30    | Oint | Erythromycin eye ointment 0.5 %, 3.5 g tube : Eye Ointment  | 3,750.00  |
| 64      | 300   | Tab  | Fenofibrate 200mg Cap   | 5,400.00  |
| <i></i> |       |      | Ferrous Salt 30 mg elemental iron / 5 ml  |           |
| 65      | 144   | Bot  | syp 60 ml : ORAL  | 3,168.00  |
| 66      | 3000  | Tab  | Ferrous Salt tab equivalent to 60 mg elemental iron : ORAL N.B. elem iron content of a ferrous salt depends on the type of prep       | 5,250.00  |
| 67      | 100   | Cap  | Fluconazole 200 mg Cap  | 28,000.00 |
| 68      | 100   | Tube | Fluocinonide .05% 5 g tube : CREAM  | 23,500.00 |
| 69      | 200   | Amp  | Furosemide 10 mg / ml 2 ml amp (im,iv) : INJ  | 2,600.00  |
| 70      | 50    | Tube | Fusidate Sodium / Fusidic Acid 2 % 5 g tube : CREAM/ ointment 2% 15g tube   | 11,000.00 |
| 71      | 30    | Amp  | Gentamicin 40 mg / ml 1 ml amp / vl<br>(im,iv) (as sulfate0 : INJ   | 810.00    |
| 72      | 3,000 | Tab  | Gliclazide 60 mg tab : ORAL   | 30,000.00 |
| 73      | 20    | vial | Hepatitis B Vaccine (recombinant DNA)<br>10micrograms/0.5mL, 5mL (10dose)   | 5,500.00  |
| 74      | 20    | via1 | Hydralazine 20 mg / ml 1 ml vial (im,iv) (as hydrochloride): INJ  | 1,000.00  |
| 75      | 100   | vial | Hydrocortisone 125 mg / ml 2 ml vial / vl<br>(iv) (as sodium succinate) : INJ   | 35,000.00 |
| 76      | 200   | Amp  | Hyoscine 20 mg / ml 1 ml amp (im,iv,sc) (as N-butylbromide) : INJ   | 11,000.00 |
| 77      | 200   | Tab  | Ibuprofen 200mg Tablet  | 800.00    |
| 78      | 144   | Bot  | Ibuprofen 200mg/5mL 60mL syrup/Suspension   | 10,080.00 |
| 79      | 50    | INJ  | Insulin Glargine pen  | 36,000.00 |
| 80      | 1,000 | Amp  | 500 mcg Ipratropium (as bromide<br>anhydrous) + 25 mg Salbutamol (as base)<br>x 2.5 ml (unit dose) : Resp. Soln (for<br>nebulization) | 20,000.00 |
| 81      | 1,000 | Cap  | Isosorbide 5 Mononitrate 60 mg SR tab / cap : ORAL  | 7,250.00  |

| 82  | 100   | Amp  | Isosorbide Dinitrate 1 mg / ml 10 ml amp (IV): INJ   | 53,000.00  |
|-----|-------|------|--|------------|
| 83  | 500   | Tab  | Isosorbide Dinitrate 5 mg tab : Sublingual   | 9,000.00   |
| 84  | 100   | Tube | Ketoconazole 20mg/g (2%w/w) 15g<br>cream aluminum collapsible tube   | 10,500.00  |
| 85  | 144   | Bot  | Lactulose 3.3 g / 5 ml (66%) syp 120 ml : ORAL   | 25,200.00  |
| 86  | 1,000 | Bot  | Lagundi 600 mg tab : ORAL  | 3,500.00   |
| 87  | 288   | Bot  | Vitex Negundo L (Lagundi Leaf) 300 mg<br>/ 5 ml syp : ORAL 60ML  | 21,600.00  |
| 88  | 50    | Vial | Lidocaine 2%, 50mL Soln for INJ vial   | 2,200.00   |
| 89  | 500   | Tab  | Loratadine 10 mg tab : ORAL  | 2,500.00   |
| 90  | 3,000 | Tab  | Losartan 100 mg tab ( as potassium salt ) : ORAL   | 15,000.00  |
| 91  | 50    | Amp  | Magnesium Sulfate 250mg /ml 20 ml amp (im,iv) (as heptahydrate) : INJ  | 2,250.00   |
| 92  | 1,500 | Cap  | Mefenamic Acid 500 mg tab/cap: ORAL  | 9,750.00   |
| 93  | ,5000 | Tab  | Metformin (as hydrochloride) 500mg   | 65,000.00  |
| 94  | 50    | Amp  | Methylergometrine (Methylergonovine)<br>200 mcg / ml 1 ml amp (im,iv) (as<br>hydrogen maleate or maleate): INJ | 4,250.00   |
| 95  | 300   | Tab  | Metoclopramide 10 mg tab (as hydrochloride): Oral  | 525.00     |
| 96  | 200   | Tab  | Metoprolol 100 mg tab (as tartrate): ORAL  | 500.00     |
| 97  | 300   | Tab  | Metronidazole 500 mg tab : ORAL  | 3,900.00   |
| 98  | 144   | Bot  | Metronidazole 125 mg base / 5 ml (200 mg / 5 ml as benzoate) susp 60 ml : ORAL                                 | 7,920.00   |
| 99  | 50    | Vial | Metronidazole 5 mg / ml, 100 ml vl ( IV infusion ): INJ  | 3,750.00   |
| 100 | 100   | Tab  | Montelukast 4 mg chewable tablet ( as sodium salt ): ORAL  | 700.00     |
| 101 | 100   | Tab  | Montelukast 5mg chewable tablet ( as sodium salt ): ORAL   | 1,500.00   |
| 102 | 100   | Tab  | Montelukast 10 mg tab ( as sodium salt ): ORAL   | 1,300.00   |
| 103 | 2,000 | Cap  | Multivitamin cap : ORAL  | 7,000.00   |
| 104 | 144   | Bot  | Multivitamins / ml drops 15mL: ORAL  | 7,920.00   |
| 105 | 288   | Bot  | Multivitamin / 5 ml syp60mL : ORAL   | 21,600.00  |
| 106 | 150   | Tube | Mupirocin 2 % 15 g : cream   | 19,500.00  |
| 107 | 10    | Amp  | Naloxone 400 mcg / ml 1 ml amp (im,iv,sc) (as hydrochloride) : INJ   | 4,000.00   |
| 108 | 100   | Cap  | Nifedipine 10MG cap  | 700.00     |
| 109 | 50    | Bot  | Nystatin 100,000 units / ml susp, 30 ml : ORAL   | 10,000.00  |
| 110 | 3,000 | Cap  | Omeprazole 20 mg cap : ORAL  | 36,000.00  |
| 111 | 3,000 | Cap  | Omeprazole 40 mg cap : ORAL  | 114,000.00 |
| 112 | 150   | Via1 | Omeprazole 40 mg Powder for INJ. Vial<br>+10mL solvent   | 30,000.00  |
| 113 | 100   | Amp  | Ondansetron 2mg/mL (2mL) amp (IM,IV)   | 20,000.00  |
| 114 | 300   | Amp  | Oxytocin 10 iu/ml, 1ml Amp (IM,IV)   | 87,000.00  |
| 115 | 3,000 | Tab  | Paracetamol 500 mg tab: ORAL   | 6,000.00   |
| 116 | 288   | Bot  | Paracetamol 100 mg / ml drops 15 ml (alcohol free): ORAL   | 11,520.00  |
| 117 | 200   | Amp  | Paracetamol 150 mg / 1 ml 2 ml amp : INJ   | 2,000.00   |
| 118 | 100   | Vial | Paracetamol 10mg/ml 100mL (IV)   | 23,000.00  |

| 119 | 50    | Supp | Paracetamol 125 mg supp : RECTAL  | 2,500.00   |
|-----|-------|------|---|------------|
| 120 | 100   | Supp | Paracetamol 250 mg supp: RECTAL   | 4,500.00   |
| 121 | 10    | INJ  | Penicillin G Benzathine (Benzathine Benzylpenicillin) 1,000.000 units vl (MR) (IM): INJ                             | 150.00     |
| 122 | 10    | INJ  | Penicillin G Benzathine (Benzathine<br>Benzylpenicillin) 1,200.000 units vl (MR)<br>(IM): INJ                       | 1,450.00   |
| 123 | 200   | INJ  | Phytomenadione (Phytonadione, Vit K1) 10 mg / ml 1 ml amp (im,iv,sc) (as aqueous coll. soln w/ benzyl alcohol): INJ | 8,600.00   |
| 124 | 50    | INJ  | Piiperacillin 2g + Tazobactam 250 per vial (as sodium salt)(IV inf) : INJ   | 14,500.00  |
| 125 | 50    | INJ  | Piiperacillin 4g + Tazobactam 500 per vial (as sodium salt)(IV inf) : INJ   | 22,000.00  |
| 126 | 144   | INJ  | Potassium Chloride 2 meq / ml 20 ml vl (IV inf) : INJ   | 7,200.00   |
| 127 | 100   | Tab  | Prednisone 5 mg tab : ORAL  | 200.00     |
| 128 | 100   | Tab  | Prednisone 10 mg tab : ORAL   | 300.00     |
| 129 | 100   | Tab  | Prednisone 20 mg tab : ORAL   | 500.00     |
| 130 | 72    | Bot  | Prednisone 10mg/5ml Susp. 60mL  | 8,640.00   |
| 131 | 500   | Vial | Purified Rabies Vaccine (Vero Cell) 2.5 I.U and 0.5 mL of solvent   | 600,000.00 |
| 132 | 20    | Vial | Regular Insulin (Recombinant DNA<br>Human) 100 IU/mL, 10mL soln for INJ<br>vial                                     | 9,900.00   |
| 133 | 1500  | Amp  | Salbutamol 1 mg / ml 2.5 ml (unit dose) (as sulfate): Resp Soln (for nebulization)                                  | 10,500.00  |
| 134 | 144   | Bot  | Salbutamol 2 mg / 5 ml syp 60 ml (as sulfate) : ORAL  | 7,200.00   |
| 135 | 500   | Tab  | Simvastatin 20 mg tab : ORAL  | 1,000.00   |
| 136 | 1000  | Tab  | Simvastatin 40 mg tab : ORAL  | 4,000.00   |
| 137 | 30    | Amp  | Sodium Bicarbonate 1 meq / ml 20 ml vl (adult) (IV inf) : INJ   | 6,900.00   |
| 138 | 100   | Tab  | Spironolactone 25 mg tab  | 1,000.00   |
| 139 | 10    | Vial | Suxamethonium ( succinylcholine ) 20 mg / ml, 10 ml vl ( IV ) (as chloride ) INJ                                    | 6,900.00   |
| 140 | 10    | Amp  | Terbutaline 500 mcg / ml 1 ml amp (IV inf) (as sulfate) : INJ   | 950.00     |
| 141 | 50    | Amp  | Tetanus Immunoglobulin (human) 250 iu/ml, 1 ml prefilled syringe (IM) : INJ   | 46,836.00  |
| 142 | 300   | Cap  | Tramadol 50 mg cap (as hydrochloride) : ORAL  | 900.00     |
| 143 | 100   | Amp  | Tranexamic Acid 100 mg / ml 5 ml amp (im,iv): INJ   | 7,500.00   |
| 144 | 10    | Amp  | 100 mg B1+ 100 mg B6 + 1 mg B12 / 3<br>ml amp m( IV ) : INJ   | 1,900.00   |
| 145 | 5,000 | Tab  | Vitamin B1B6B12 tab   | 40,000.00  |
| 146 | 288   | Bot  | Zinc (Equivalent to 10mg elementalzinc/mL) Drops 15mL, (as Sulfate monohydrate)                                     | 17,280.00  |
| 147 | 288   | Bot  | Zinc (Equivalent to 20mg<br>elementalzinc/mL) Syrup 60mL, (as<br>Sulfate monohydrate)                               | 10,080.00  |
| 148 | 240   | Bot  | 5 % Dextrose in Lactated Ringer's 1 L bot (IV inf): INJ.  | 21,600.00  |
| 149 | 288   | Bot  | 5 % Dextrose in 0.3 % Sodium Chloride<br>500 ml bot ( IV inf ) INJ.   | 17,280.00  |

| 150 | 100 | Bot | 5 % Dextrose in Water 250 ml bot ( IV inf and as which for IV medications ): INJ. | 9,000.00  |
|-----|-----|-----|---|-----------|
| 151 | 50  | Bot | Glucose ( dextrose ) 50 % 50 ml ( 85 K cal ) vl ( IV ) : INJ.                     | 3,750.00  |
| 152 | 480 | Bot | 0.9 % Sodium Chloride 500 ml bot ( IV inf ): INJ.                                 | 24,000.00 |
| 153 | 300 | Bot | 0.9 % Sodium Chloride 1 L bot ( IV inf ): INJ.                                    | 34,500.00 |
| 154 | 120 | Bot | 0.9% Sodium Chloride 1L (Irrigating Solution)                                     | 8,400.00  |
| 155 | 120 | Bot | Lactated Ringer's Solution (Ringer's lactate) 500 ml bot (IV inf): INJ.           | 6,000.00  |
| 156 | 120 | Bot | Lactated Ringer's Solution (Ringer's lactate) 1 L bot (IV inf): INJ.              | 10,800.00 |

- 2. The City Government of Naga invites bids for the above Procurement Project. Delivery of the Goods is required within thirty (30) calendar days after the issuance of the Notice to Proceed (NTP). Bidders should have completed a contract similar to the Project within the last five (5) years from the date of submission and receipt of bids. The description of an eligible bidder is contained in the Bidding Documents, specifically in Section II (Instructions to Bidders).
- 3. Bidding will be conducted through open competitive bidding procedures using a non-discretionary "pass/fail" criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) No. 9184.
  - Bidding is open to all interested bidders, whether local or foreign, subject to the conditions for eligibility provided in the 2016 revised IRR of RA No. 9184.
- 4. Prospective Bidders may obtain further information from Local Government Unit of Naga City and inspect the Bidding Documents at the BAC Secretariat Office, Room 208, Second Floor, City Hall Building, City Hall Compound from 8:00AM to 5:00PM. The 6<sup>th</sup> edition of the Philippine Bidding Documents (PBDs) will be used.
- 5. A complete set of Bidding Documents may be acquired by interested Bidders on Tuesday, February 13, 2024 to Friday, March 1, 2024 from the BAC Secretariat Office, Room 208 Second Floor, City Hall Building, City Hall Compound and may be downloaded at websites, naga.gov.ph and www.philgeps.gov.ph and upon payment of the applicable fee for the Bidding Documents, pursuant to the latest Guidelines issued by the GPPB, in the amount of **Five Thousand (P 5,000.00) Pesos**. The Procuring Entity shall allow the bidder to present its proof of payment for the fees in person during the dropping of bids.
- 6. The City Government of Naga will hold a **Pre-Bid Conference** on Wednesday, February 21, 2024 at 3:00PM at the City Procurement Office, Room 107, Ground Floor, Main Building, City Hall Compound, which shall be open to prospective bidders.
- 7. Bids must be duly received by the BAC Secretariat through manual submission at the City Procurement Office, Ground Floor, City Hall Building, City Hall Compound, on or before 3:00PM on Monday, March 4, 2024. Late bids shall not be accepted.
- 8. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in ITB Clause 14.
- 9. **Bid opening** shall be on Monday, March 4, 2024, 3:00PM at the City Procurement Office, Ground Floor, City Hall Building, City Hall Compound. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.
- 10. Additional information:
  - a) An Annual Registration Fee of Three Thousand (P 3,000.00) Pesos is required.
  - b) Forms in the PBD should be used in submitting proposals and should remain unaltered.

- c) Bidders are strongly encouraged to download the digital copy of the Bid Documents utilizing the PhilGEPS DRL facility.
- 11. The City Government of Naga reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections 35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.
- 12. For further information, please refer to:

#### ENGR. ALEXANDER N. CANING

Acting City Engineer, City Engineer's Office 1st Floor City Hall Building, City Hall Compound, J. Miranda Avenue Concepcion Pequena, Naga City 4400

Mobile Number: +639175801165

Email address: bac@naga.gov.ph, alexandercaning@gmail.com

Website: www.naga.gov.ph

13. For downloading of bidding documents, you may visit the following

websites: www.philgeps.gov.ph / www.naga.gov.ph

Date of Issue: February 13, 2024 to February 22, 2024

ENGR. ALEXANDER IN. CANING Chairperson, Bids and Awards Committee

#### Section II. Instructions to Bidders

#### 1. Scope of Bid

The Procuring Entity, City Government of Naga wishes to receive Bids for the Supply and Delivery of Drugs and Medicines for use in the NCGH Operations, with identification number Project/Contract Reference Number: 2024-005.

The Procurement Project (referred to herein as "Project") is composed of 1 item, the details of which are described in Section VII (Technical Specifications).

#### 2. Funding Information

- 2.1. The LGU through the source of funding as indicated below for Year 2024 in the amount of Three Million Three Hundred Eighty-Five Thousand Five Hundred Forty-Nine (P 3,385,549.00) Pesos.
- 2.2. The source of funding is: Naga City General Hospital (NCGH) Drugs and Medicines account, the Annual or Supplemental Budget, as approved by the Sanggunian.

#### 3. Bidding Requirements

The Bidding for the Project shall be governed by all the provisions of RA No. 9184 and its 2016 revised IRR, including its Generic Procurement Manuals and associated policies, rules and regulations as the primary source thereof, while the herein clauses shall serve as the secondary source thereof.

Any amendments made to the IRR and other GPPB issuances shall be applicable only to the ongoing posting, advertisement, or **IB** by the BAC through the issuance of a supplemental or bid bulletin.

The Bidder, by the act of submitting its Bid, shall be deemed to have verified and accepted the general requirements of this Project, including other factors that may affect the cost, duration and execution or implementation of the contract, project, or work and examine all instructions, forms, terms, and project requirements in the Bidding Documents.

#### 4. Corrupt, Fraudulent, Collusive, and Coercive Practices

The Procuring Entity, as well as the Bidders and Suppliers, shall observe the highest standard of ethics during the procurement and execution of the contract. They or through an agent shall not engage in corrupt, fraudulent, collusive, coercive, and obstructive practices defined under Annex "I" of the 2016 revised IRR of RA No. 9184 or other integrity violations in competing for the Project.

#### 5. Eligible Bidders

- 5.1. Only Bids of Bidders found to be legally, technically, and financially capable will be evaluated.
- 5.2. Foreign ownership exceeding those allowed under the rules may participate pursuant to:
  - i. When a Treaty or International or Executive Agreement as provided in Section 4 of the RA No. 9184 and its 2016 revised IRR allow foreign bidders to participate;
  - ii. Citizens, corporations, or associations of a country, included in the list issued by the GPPB, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;
  - iii. When the Goods sought to be procured are not available from local suppliers; or
  - iv. When there is a need to prevent situations that defeat competition or restrain trade.

Foreign ownership limited to those allowed under the rules may participate in this Project.

- 5.3. Pursuant to Section 23.4.1.3 of the 2016 revised IRR of RA No.9184, the Bidder shall have an SLCC that is at least one (1) contract similar to the Project the value of which, adjusted to current prices using the PSA's CPI, must be at least equivalent to:
  - a. For the procurement of Non-expendable Supplies and Services: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least fifty percent (50%) of the ABC.
  - b. For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC.
  - c. For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of either (a) or (b) will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: the Bidder should comply with the following requirements:
    - i. Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least fifty percent (50%) in the case of non-expendable supplies and services or twenty-five percent (25%) in the case of expendable supplies] of the ABC for this Project; and

- ii. The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.
- 5.4. The Bidders shall comply with the eligibility criteria under Section 23.4.1 of the 2016 IRR of RA No. 9184.

#### 6. Origin of Goods

There is no restriction on the origin of goods other than those prohibited by a decision of the UN Security Council taken under Chapter VII of the Charter of the UN, subject to Domestic Preference requirements under **ITB** Clause 18.

#### 7. Subcontracts

7.1. The Bidder may subcontract portions of the Project to the extent allowed by the Procuring Entity as stated herein, but in no case more than twenty percent (20%) of the Project.

The Procuring Entity has prescribed that: Subcontracting is not allowed.

#### 8. Pre-Bid Conference

The Procuring Entity will hold a pre-bid conference for this Project on the specified date and time and either at the City Procurement Office, Room 107, Ground Floor, Main Building, City Hall Compound, Naga City, as indicated in paragraph 6 of the IB.

#### 9. Clarification and Amendment of Bidding Documents

Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such requests must be in writing and received by the Procuring Entity, either at its given address or through electronic mail indicated in the **IB**, at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

# 10. Documents comprising the Bid: Eligibility and Technical Components

- 10.1. The first envelope shall contain the eligibility and technical documents of the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.
- 10.2. The Bidder's SLCC as indicated in **ITB** Clause 5.3 should have been completed within five (5) years prior to the deadline for the submission and receipt of bids.
- 10.3. If the eligibility requirements or statements, the bids, and all other documents for submission to the BAC are in foreign language other than

English, it must be accompanied by a translation in English, which shall be authenticated by the appropriate Philippine foreign service establishment, post, or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. Similar to the required authentication above, for Contracting Parties to the Apostille Convention, only the translated documents shall be authenticated through an apostille pursuant to GPPB Resolution No. 13-2019 dated 23 May 2019. The English translation shall govern, for purposes of interpretation of the bid.

#### 11. Documents comprising the Bid: Financial Component

- 11.1. The second bid envelope shall contain the financial documents for the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.
- 11.2. If the Bidder claims preference as a Domestic Bidder or Domestic Entity, a certification issued by DTI shall be provided by the Bidder in accordance with Section 43.1.3 of the 2016 revised IRR of RA No. 9184.
- 11.3. Any bid exceeding the ABC indicated in paragraph 1 of the **IB** shall not be accepted.
- 11.4. For Foreign-funded Procurement, a ceiling may be applied to bid prices provided the conditions are met under Section 31.2 of the 2016 revised IRR of RA No. 9184.

#### 12. Bid Prices

- 12.1. Prices indicated on the Price Schedule shall be entered separately in the following manner:
  - a. For Goods offered from within the Procuring Entity's country:
    - i. The price of the Goods quoted EXW (ex-works, ex-factory, ex-warehouse, ex-showroom, or off-the-shelf, as applicable);
    - ii. The cost of all customs duties and sales and other taxes already paid or payable;
    - iii. The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and
    - iv. The price of other (incidental) services, if any, listed in the **BDS.**
  - b. For Goods offered from abroad:
    - i. Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted delivered duty paid (DDP) with the place of destination in the Philippines as specified in the **BDS**. In

quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.

ii. The price of other (incidental) services, if any, as listed in the **BDS.** 

#### 13. Bid and Payment Currencies

- 13.1. For Goods that the Bidder will supply from outside the Philippines, the bid prices may be quoted in the local currency or tradeable currency accepted by the BSP at the discretion of the Bidder. However, for purposes of bid evaluation, Bids denominated in foreign currencies, shall be converted to Philippine currency based on the exchange rate as published in the BSP reference rate bulletin on the day of the bid opening.
- 13.2 Payment of the contract price shall be made in: Philippine Pesos.

#### 14. Bid Security

- 14.1. The Bidder shall submit a Bid Securing Declaration<sup>1</sup> or any form of Bid Security in the amount indicated in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the schedule in the **BDS**.
- 14.2. The Bid and bid security shall be valid within one hundred twenty (120) calendar days from date of opening of bids. Any Bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.

#### 15. Sealing and Marking of Bids

Each Bidder shall submit one copy of the first and second components of its Bid.

The Procuring Entity may request additional hard copies and/or electronic copies of the Bid. However, failure of the Bidders to comply with the said request shall not be a ground for disqualification.

If the Procuring Entity allows the submission of bids through online submission or any other electronic means, the Bidder shall submit an electronic copy of its Bid, which must be digitally signed. An electronic copy that cannot be opened or is corrupted shall be considered non-responsive and, thus, automatically disqualified.

#### 16. Deadline for Submission of Bids

-

<sup>&</sup>lt;sup>1</sup> In the case of Framework Agreement, the undertaking shall refer to entering into contract with the Procuring Entity and furnishing of the performance security or the performance securing declaration within ten (10) calendar days from receipt of Notice to Execute Framework Agreement.

16.1. The Bidders shall submit on the specified date and time and either at its physical address or through online submission as indicated in paragraph 7 of the **IB**.

#### 17. Opening and Preliminary Examination of Bids

17.1. The BAC shall open the Bids in public at the time, on the date, and at the place specified in paragraph 9 of the **IB**. The Bidders' representatives who are present shall sign a register evidencing their attendance. In case videoconferencing, webcasting or other similar technologies will be used, attendance of participants shall likewise be recorded by the BAC Secretariat.

In case the Bids cannot be opened as scheduled due to justifiable reasons, the rescheduling requirements under Section 29 of the 2016 revised IRR of RA No. 9184 shall prevail.

17.2. The preliminary examination of bids shall be governed by Section 30 of the 2016 revised IRR of RA No. 9184.

#### 18. Domestic Preference

18.1. The Procuring Entity will grant a margin of preference for the purpose of comparison of Bids in accordance with Section 43.1.2 of the 2016 revised IRR of RA No. 9184.

#### 19. Detailed Evaluation and Comparison of Bids

- 19.1. The Procuring Entity's BAC shall immediately conduct a detailed evaluation of all Bids rated "passed," using non-discretionary pass/fail criteria. The BAC shall consider the conditions in the evaluation of Bids under Section 32.2 of the 2016 revised IRR of RA No. 9184.
- 19.2. If the Project allows partial bids, bidders may submit a proposal on any of the lots or items, and evaluation will be undertaken on a per lot or item basis, as the case maybe. In this case, the Bid Security as required by **ITB** Clause 14 shall be submitted for each lot or item separately.
- 19.3. The descriptions of the lots or items shall be indicated in **Section VII** (**Technical Specifications**), although the ABCs of these lots or items are indicated in the **BDS** for purposes of the NFCC computation pursuant to Section 23.4.2.6 of the 2016 revised IRR of RA No. 9184. The NFCC must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder.
- 19.4. The Project shall be awarded as One Project having several items that shall be awarded as one contract.
- 19.5. Except for bidders submitting a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, all Bids must include

the NFCC computation pursuant to Section 23.4.1.4 of the 2016 revised IRR of RA No. 9184, which must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder. For bidders submitting the committed Line of Credit, it must be at least equal to ten percent (10%) of the ABCs for all the lots or items participated in by the prospective Bidder.

#### 20. Post-Qualification

20.2. Within a non-extendible period of five (5) calendar days from receipt by the Bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the BDS.

#### 21. Signing of the Contract

21.1. The documents required in Section 37.2 of the 2016 revised IRR of RA No. 9184 shall form part of the Contract. Additional Contract documents are indicated in the **BDS**.

## Section III. Bid Data Sheet

# **Bid Data Sheet**

| ITB    |   |
|--------|---|
| Clause |   |
| 5.3    | For this purpose, contracts similar to the Project shall be:  |
|        | <ul> <li>a. Supply and Delivery of Drugs and Medicines and other related procurement activities.</li> <li>b. Completed within five (5) years prior to the deadline for the submission and receipt of bids.</li> </ul> |
| 14.1   | The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts:   |
|        | a. The amount of not less than P 67,710.98 [equivalent to two percent (2%) of ABC], if bid security is in cash, cashier's/manager's check, bank draft/guarantee or irrevocable letter of credit; or                   |
|        | b. The amount of not less than P 169,277.45 [equivalent to five percent (5%) of ABC] if bid security is in Surety Bond.   |

# Section IV. General Conditions of Contract

#### 1. Scope of Contract

This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. All the provisions of RA No. 9184 and its 2016 revised IRR, including the Generic Procurement Manual, and associated issuances, constitute the primary source for the terms and conditions of the Contract, and thus, applicable in contract implementation. Herein clauses shall serve as the secondary source for the terms and conditions of the Contract.

This is without prejudice to Sections 74.1 and 74.2 of the 2016 revised IRR of RA No. 9184 allowing the GPPB to amend the IRR, which shall be applied to all procurement activities, the advertisement, posting, or invitation of which were issued after the effectivity of the said amendment.

Additional requirements for the completion of this Contract shall be provided in the **Special Conditions of Contract (SCC).** 

#### 2. Advance Payment and Terms of Payment

- 2.1. Advance payment of the contract amount is provided under Annex "D" of the revised 2016 IRR of RA No. 9184.
- 2.2. The Procuring Entity is allowed to determine the terms of payment on the partial or staggered delivery of the Goods procured, provided such partial payment shall correspond to the value of the goods delivered and accepted in accordance with prevailing accounting and auditing rules and regulations. The terms of payment are indicated in the **SCC**.

#### 3. Performance Security

Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than the signing of the Contract by both parties, the successful Bidder shall furnish the performance security in any of the forms prescribed in Section 39 of the 2016 revised IRR of RA No. 9184

#### 4. Inspection and Tests

The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Project specifications at no extra cost to the Procuring Entity in accordance with the Generic Procurement Manual. In addition to tests in the SCC, Section VII (Technical Specifications) shall specify what inspections and/or tests the Procuring Entity requires, and where they are to

be conducted. The Procuring Entity shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

All reasonable facilities and assistance for the inspection and testing of Goods, including access to drawings and production data, shall be provided by the Supplier to the authorized inspectors at no charge to the Procuring Entity.

#### 5. Warranty

- 5.1 In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier as provided under Section 62.1 of the 2016 revised IRR of RA No. 9184.
- 5.2 The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, repair or replace the defective Goods or parts thereof without cost to the Procuring Entity, pursuant to the Generic Procurement Manual.

#### 6. Liability of the Supplier

The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines.

If the Supplier is a joint venture, all partners to the joint venture shall be jointly and severally liable to the Procuring Entity.

# Section V. Special Conditions of Contract

## **Special Conditions of Contract**

| GCC    |  |  |  |  |  |  |  |
|--------|--|--|--|--|--|--|--|
| Clause |  |  |  |  |  |  |  |
| 1      | Delivery and Documents –   |  |  |  |  |  |  |
| 1      | For purposes of the Contract, "EXW," "FOB," "FCA," "CIF," "CIP,"   |  |  |  |  |  |  |
|        | "DDP" and other trade terms used to describe the obligations of the parties  |  |  |  |  |  |  |
|        | shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, |  |  |  |  |  |  |
|        |  |  |  |  |  |  |  |
|        | Paris. The Delivery terms of this Contract shall be as follows:  |  |  |  |  |  |  |
|        | "The delivery terms applicable to the Contract are DDP delivered in Naga   |  |  |  |  |  |  |
|        | City. In accordance with INCOTERMS."   |  |  |  |  |  |  |
|        | "The delivery terms applicable to this Contract are delivered in Naga City.  |  |  |  |  |  |  |
|        | Risk and title will pass from the Supplier to the Procuring Entity upon  |  |  |  |  |  |  |
|        | receipt and final acceptance of the Goods at their final destination."   |  |  |  |  |  |  |
|        | Delivery of the Goods shall be made by the Supplier in accordance with the   |  |  |  |  |  |  |
|        | terms specified in Section VI (Schedule of Requirements).  |  |  |  |  |  |  |
|        | For purposes of this Clause the Procuring Entity's Representative is Dr.   |  |  |  |  |  |  |
|        | Joseph S. Sanchez, Chief of Hospital   |  |  |  |  |  |  |
|        | Incidental Services –  |  |  |  |  |  |  |
|        | The Supplier is required to provide all of the following services, including   |  |  |  |  |  |  |
|        | additional services, if any, specified in Section VI. Schedule of  |  |  |  |  |  |  |
|        | Requirements:  |  |  |  |  |  |  |
|        | a. performance or supervision of on-site assembly and/or start-u   |  |  |  |  |  |  |
|        | of the supplied Goods;   |  |  |  |  |  |  |
|        | b. furnishing of tools required for assembly and/or maintenance of the supplied Goods;   |  |  |  |  |  |  |
|        | c. furnishing of a detailed operations and maintenance manual for  |  |  |  |  |  |  |
|        | each appropriate unit of the supplied Goods;   |  |  |  |  |  |  |
|        | d. performance or supervision or maintenance and/or repair of the  |  |  |  |  |  |  |
|        | supplied Goods, for a period of time agreed by the parties,  |  |  |  |  |  |  |
|        | provided that this service shall not relieve the Supplier of any   |  |  |  |  |  |  |
|        | warranty obligations under this Contract; and  |  |  |  |  |  |  |
|        | e. training of the Procuring Entity's personnel, at the Supplier's   |  |  |  |  |  |  |
|        | plant and/or on-site, in assembly, start-up, operation,  |  |  |  |  |  |  |
|        | maintenance, and/or repair of the supplied Goods.  |  |  |  |  |  |  |
|        | The Contract price for the Goods shall include the prices charged by the   |  |  |  |  |  |  |
|        | Supplier for incidental services and shall not exceed the prevailing rates   |  |  |  |  |  |  |
|        | charged to other parties by the Supplier for similar services.   |  |  |  |  |  |  |
|        | Spare Parts –  |  |  |  |  |  |  |
|        | The Supplier is required to provide all of the following materials,  |  |  |  |  |  |  |
|        | notifications, and information pertaining to spare parts manufactured or   |  |  |  |  |  |  |
|        | distributed by the Supplier:   |  |  |  |  |  |  |

| 1. such spare parts as the Procuring Entity may elect to purchase from   |
|--|
| the Supplier, provided that this election shall not relieve the Supplier   |
| of any warranty obligations under this Contract; and   |
| 2. in the event of termination of production of the spare parts:   |
| i. advance notification to the Procuring Entity of the pending   |
| termination, in sufficient time to permit the Procuring Entity to  |
| procure needed requirements; and   |
| ii. following such termination, furnishing at no cost to the   |
| Procuring Entity, the blueprints, drawings, and specifications of  |
| the spare parts, if requested.   |
| The spare parts and other components required are listed in <b>Section VI</b>  |
| (Schedule of Requirements) and the costs thereof are included in the   |
| contract price.  |
| The Supplier shall carry sufficient inventories to assure ex-stock supply of consumable spare parts or components for the goods. |
|  |
| Spare parts or components shall be supplied as promptly as possible.   |
| Packaging –  |
| The Supplier shall provide such packaging of the Goods as is required to   |
| prevent their damage or deterioration during transit to their final  |
| destination, as indicated in this Contract. The packaging shall be sufficient  |
| to withstand, without limitation, rough handling during transit and  |
| exposure to extreme temperatures, salt and precipitation during transit, and   |
| open storage. Packaging case size and weights shall take into consideration,   |
| where appropriate, the remoteness of the Goods' final destination and the  |
| absence of heavy handling facilities at all points in transit.   |
| The packaging, marking, and documentation within and outside the   |
| packages shall comply strictly with such special requirements as shall be  |
| expressly provided for in the Contract, including additional requirements,   |
| if any, specified below, and in any subsequent instructions ordered by the   |
| Procuring Entity.  |
| The outer packaging must be clearly marked on at least four (4) sides as   |
| follows:   |
| Name of the Procuring Entity: Local Government Unit of Naga City   |
| Name of the Supplier   |
| Contract Description: Drugs and Medicines  |
| Final Destination: Naga City General Hospital, LGU of Naga City  |
| Gross weight   |
| Any special lifting instructions   |
| Any special handling instructions  |
| Any relevant HAZCHEM classifications   |
| A packaging list identifying the contents and quantities of the package is to  |
| be placed on an accessible point of the outer packaging if practical. If not   |
| practical the packaging list is to be placed inside the outer packaging but  |
| outside the secondary packaging.   |
| Transportation –   |
| Where the Supplier is required under Contract to deliver the Goods CIF,  |
| CIP, or DDP, transport of the Goods to the port of destination or such other   |

|   | 1 1 0 1 2 2 1 1 10 11 1 11 1 10 1 1 1 1  |
|---|--|
|   | named place of destination in the Philippines, as shall be specified in this   |
|   | Contract, shall be arranged and paid for by the Supplier, and the cost thereof |
|   | shall be included in the Contract Price.                                       |
|   | Where the Supplier is required under this Contract to transport the Goods      |
|   | to a specified place of destination within the Philippines, defined as the     |
|   | Project Site, transport to such place of destination in the Philippines,       |
|   | including insurance and storage, as shall be specified in this Contract, shall |
|   | be arranged by the Supplier, and related costs shall be included in the        |
|   | contract price.  |
|   | Where the Supplier is required under Contract to deliver the Goods CIF,        |
|   | CIP or DDP, Goods are to be transported on carriers of Philippine registry.    |
|   | In the event that no carrier of Philippine registry is available, Goods may be |
|   | shipped by a carrier which is not of Philippine registry provided that the     |
|   | Supplier obtains and presents to the Procuring Entity certification to this    |
|   | effect from the nearest Philippine consulate to the port of dispatch. In the   |
|   |  |
|   | event that carriers of Philippine registry are available but their schedule    |
|   | delays the Supplier in its performance of this Contract the period from when   |
|   | the Goods were first ready for shipment and the actual date of shipment the    |
| _ | period of delay will be considered force majeure.                              |
|   | The Procuring Entity accepts no liability for the damage of Goods during       |
|   | transit other than those prescribed by INCOTERMS for DDP deliveries. In        |
|   | the case of Goods supplied from within the Philippines or supplied by          |
|   | domestic Suppliers risk and title will not be deemed to have passed to the     |
|   | Procuring Entity until their receipt and final acceptance at the final         |
|   | destination.   |
|   | Intellectual Property Rights –   |
|   | The Supplier shall indemnify the Procuring Entity against all third-party      |
|   | claims of infringement of patent, trademark, or industrial design rights       |
|   | arising from use of the Goods or any part thereof.                             |
| 4 | The inspections and tests that will be conducted are: the General Services     |
|   | Office (GSO), City Budget Office (CBO), and the End-User Unit/Office (NCGH).   |
|   | Terms of Payment –   |
|   | Supplier may claim for progress billing on every completed, inspected, and     |
|   | accepted delivery as indicated in the delivery period as stated in the         |
|   | Invitation to Bid. Attached with the delivery receipt, the supplier is to      |
|   | issue and submit a statement of account to the procuring unit for progress     |
|   | payment processing within 30 days.   |
|   |  |

# Section VI. Schedule of Requirements

The delivery schedule expressed as days/weeks/months stipulates hereafter a delivery date which is the date of delivery to the project site.

| Item<br>No. | Description   | Qty    | Total | Delivered, Days/Weeks/Months |
|-------------|---|--------|-------|------------------------------|
| 1           | Acetylcysteine 600 mg effervescent tab : ORAL   | 1,000  |       |                              |
| 2           | Adenosine 3mg/ml 2ml Amp/Vial   | 10     |       |                              |
| 3           | Allopurinol 100 mg tab : ORAL   | 500    |       |                              |
| 4           | Aminophylline ( theophylline ethylenediamine ) 25 mg / ml 10 ml amp IV : INJ                  | 10     |       |                              |
| 5           | Amiodarone 200 mg tab (as hydrochloride) : ORAL   | 100    |       |                              |
| 6           | Amiodarone 50 mg / ml, 3 ml amp ( IV ) ( as hydrochloride ): INJ                              | 10     |       |                              |
| 7           | Amlodipine 5 mg tab (as besilate): ORAL   | 20,000 |       |                              |
| 8           | Amlodipine 10 mg tab (as besilate): ORAL  | 10,000 |       |                              |
| 9           | Amoxicillin 500 mg cap (as trihydrate): ORAL  | 3,000  |       |                              |
| 10          | Amoxicillin 100 mg / ml granules / powder for drops (suspension) 10 ml (as trihydrate) : ORAL | 144    |       |                              |
| 11          | Amoxicillin 250 mg / 5 ml granules / powder for susp 60 ml (as trihydrate) : ORAL             | 144    |       |                              |
| 12          | Ampicillin 500 mg vl (im,iv) (as sodium salt): INJ  | 30     |       |                              |
| 13          | Ampicillin 500mg Sulbactam250mg (as sodium salt) / vl (im,iv) : INJ                           | 200    |       |                              |
| 14          | Anti Rabies Serum (equine) 200 iu ml / 5 ml vl (im) : INJ                                     | 300    |       |                              |
| 15          | Anti Tetanus Serum (equine) 1500 iu /0.7 ml 0.7 ml vl / amp (im) : INJ                        | 2,500  |       |                              |
| 16          | Ascorbic Acid (Vit C) 500 mg tab : ORAL   | 3,000  |       |                              |
| 17          | Ascorbic Acid (Vit C) 100 mg / ml drops<br>15ml : ORAL  | 144    |       |                              |
| 18          | Ascorbic Acid (Vit C) 100 mg / 5 ml syr 60 ml : ORAL  | 144    |       |                              |
| 19          | Atorvastatin Calcium 20mg Tab   | 3,000  |       |                              |
| 20          | Atracurium (as Besilate) 10mg/mL (2.5mL/5mL) (IV)   | 50     |       |                              |
| 21          | Atropine 1 mg / ml 1 ml amp (im,iv) (as sulfate): INJ   | 10     |       |                              |
| 22          | Azithromycin 500 mg tab (as base / as dihydrate): ORAL  | 3,000  |       |                              |
| 23          | BCG Vaccine (freeze-dried powder, 100micrograms/0.1 mL, 1mL)                                  | 100    |       |                              |
| 24          | Betahistine (as<br>Hydrochloride/dihydrochloride) 16mg,<br>Tablet                             | 150    |       |                              |

| ·  |  |       |  |
|----|--|-------|--|
| 25 | Betahistine (as<br>Hydrochloride/dihydrochloride) 24mg<br>Tablet   | 300   |  |
| 26 | Biphasic Isophane human insulin 70 / 30 (recombinant DNA) 70 %isophane susp. 30 % sol. insulin in 100 iu /ml 10mL vl | 30    |  |
| 27 | (IM,SC): INJ<br>Bisacodyl 5 mg tab: ORAL   | 100   |  |
| 28 | Bisacodyl 5 mg (children) supp :   | 30    |  |
|    | RECTAL   |       |  |
| 29 | Bisacodyl 10 mg (adult) supp : RECTAL Bupivacaine Hydrochloride solution for   | 30    |  |
| 30 | spinal injection, 0.5% Heavy, 4 ml amp :<br>Local Anesthetic   | 100   |  |
| 31 | Butamirate 50 mg MR/SRtab (as citrate) : ORAL  | 1,000 |  |
| 32 | Butorphanol (as Tartrate) 2mg/mL Soln for INJ (IM/IV)  | 70    |  |
| 33 | Calcium Gluconate 10 %, 10 ml amp / vl (IV): INJ   | 20    |  |
| 34 | Carboprost250mcg/ml amp/vial   | 10    |  |
| 35 | Cefalexin 100 mg / ml granules / powder for drops 15 ml (as monohydrate) : ORAL                                      | 144   |  |
| 36 | Cefixime 200 mg Tab: ORAL  | 200   |  |
| 37 | Cefixime (as trihydrate ) 20 mg/mL , 10mL drops  | 144   |  |
| 38 | Cefixime (as trihydrate ) 100 mg/5mL , 60mL suspension   | 144   |  |
| 39 | Ceftazidime 500 mg vl (im,iv) ( as pentahydrate ): INJ   | 30    |  |
| 40 | Ceftazidime 1 g vl (im,iv) ( as pentahydrate ): INJ  | 30    |  |
| 41 | Ceftriaxone 1 g vl 10 ml diluent (iv) (as disodium sodium salt) : INJ  | 200   |  |
| 42 | Cefuroxime 500 mg tab ( as axetil ): ORAL  | 2,000 |  |
| 43 | Cefuroxime 750 mg vl (im,iv) (as sodium salt): INJ   | 50    |  |
| 44 | Cefuroxime 250 mg / 5 ml granules for susp, 50 ml : ORAL   | 288   |  |
| 45 | Cetirizine 2.5 mg / ml syrup (oral drops ) 10mL  | 144   |  |
| 46 | Ciprofloxacin 500mg Tab  | 500   |  |
| 47 | Clarithromycin 125 mg / 5 ml   | 500   |  |
| 48 | Clarithromycin 125 mg / 5 ml granules/powder for susp, 25 ml : ORAL  | 144   |  |
| 49 | Clonidine 75mcg Tab  | 400   |  |
| 50 | Clopidogrel 75 mg tab : ORAL   | 1,500 |  |
| 51 | Cloxacillin 250 mg / 5 ml powder for syr / susp 60 ml (as sodium salt) : ORAL  | 144   |  |
| 52 | Co Amoxiclav Susp 200mg/28.5mg/5ml 70ml  | 288   |  |
| 53 | Co Amoxiclav 457mg/5mL, 70 mL  | 288   |  |
| 54 | Cotrimoxazole (sulfamethoxazole + trimethoprim) 200 mg + 40 mg / 5 ml susp 60 ml : ORAL                              | 72    |  |
| 55 | Diclofenac 25 mg / ml, 3 ml amp ( IM, IV ) ( as sodium salt ) : INJ  | 10    |  |
| 56 | Digoxin 250 mcg (.25 mg) tab : ORAL  | 100   |  |

| 57 | Digoxin 250 mcg / ml 2 ml amp (im,iv) : INJ   | 20    |  |
|----|---|-------|--|
| 58 | Dobutamine 50 mg / ml ,5mL , 0.5m l solution for injection vial : INJ   | 10    |  |
| 59 | Domperidone 10 mg tab : ORAL  | 100   |  |
| 60 | Enoxaparin 40 mg / 0.4 ml prefilled syringe (SC) (as sodium) :INJ   | 30    |  |
| 61 | Epinephrine (Adrenaline) 1 mg / ml 1 ml amp (im,sc) (as hydrochloride) : INJ  | 50    |  |
| 62 | Erythromycin 500 mg tab (as stearate): ORAL   | 300   |  |
| 63 | Erythromycin eye ointment 0.5 %, 3.5 g tube : Eye Ointment  | 30    |  |
| 64 | Fenofibrate 200mg Cap   | 300   |  |
| 65 | Ferrous Salt 30 mg elemental iron / 5 ml syp 60 ml : ORAL   | 144   |  |
| 66 | Ferrous Salt tab equivalent to 60 mg elemental iron: ORAL N.B. elem iron content of a ferrous salt depends on the type of prep        | 3000  |  |
| 67 | Fluconazole 200 mg Cap  | 100   |  |
| 68 | Fluocinonide .05% 5 g tube : CREAM  | 100   |  |
| 69 | Furosemide 10 mg / ml 2 ml amp (im,iv) : INJ  | 200   |  |
| 70 | Fusidate Sodium / Fusidic Acid 2 % 5 g tube : CREAM/ ointment 2% 15g tube   | 50    |  |
| 71 | Gentamicin 40 mg / ml 1 ml amp / vl<br>(im,iv) (as sulfate0 : INJ   | 30    |  |
| 72 | Gliclazide 60 mg tab : ORAL   | 3,000 |  |
| 73 | Hepatitis B Vaccine (recombinant DNA)<br>10micrograms/0.5mL, 5mL (10dose)   | 20    |  |
| 74 | Hydralazine 20 mg / ml 1 ml vial (im,iv) (as hydrochloride) : INJ   | 20    |  |
| 75 | Hydrocortisone 125 mg / ml 2 ml vial / vl (iv) (as sodium succinate) : INJ  | 100   |  |
| 76 | Hyoscine 20 mg / ml 1 ml amp (im,iv,sc) (as N-butylbromide) : INJ   | 200   |  |
| 77 | Ibuprofen 200mg Tablet  | 200   |  |
| 78 | Ibuprofen 200mg/5mL 60mL  | 144   |  |
|    | syrup/Suspension  |       |  |
| 79 | Insulin Glargine pen  | 50    |  |
| 80 | 500 mcg Ipratropium (as bromide<br>anhydrous) + 25 mg Salbutamol (as base)<br>x 2.5 ml (unit dose) : Resp. Soln (for<br>nebulization) | 1,000 |  |
| 81 | Isosorbide 5 Mononitrate 60 mg SR tab / cap : ORAL  | 1,000 |  |
| 82 | Isosorbide Dinitrate 1 mg / ml 10 ml amp (IV): INJ  | 100   |  |
| 83 | Isosorbide Dinitrate 5 mg tab : Sublingual  | 500   |  |
| 84 | Ketoconazole 20mg/g (2%w/w) 15g cream aluminum collapsible tube   | 100   |  |
| 85 | Lactulose 3.3 g / 5 ml (66%) syp 120 ml : ORAL  | 144   |  |
| 86 | Lagundi 600 mg tab : ORAL   | 1,000 |  |
| 87 | Vitex Negundo L (Lagundi Leaf) 300 mg<br>/ 5 ml syp : ORAL 60ML   | 288   |  |
| 88 | Lidocaine 2%, 50mL Soln for INJ vial  | 50    |  |

| *   |  |       |  |
|-----|--|-------|--|
| 89  | Loratadine 10 mg tab : ORAL  | 500   |  |
| 90  | Losartan 100 mg tab ( as potassium salt ): ORAL  | 3,000 |  |
| 91  | Magnesium Sulfate 250mg /ml 20 ml amp (im,iv) (as heptahydrate) : INJ  | 50    |  |
| 92  | Mefenamic Acid 500 mg tab/cap: ORAL  | 1,500 |  |
| 93  | Metformin (as hydrochloride) 500mg   | ,5000 |  |
| 94  | Methylergometrine (Methylergonovine)<br>200 mcg / ml 1 ml amp (im,iv) (as<br>hydrogen maleate or maleate): INJ | 50    |  |
| 95  | Metoclopramide 10 mg tab (as hydrochloride) : Oral   | 300   |  |
| 96  | Metoprolol 100 mg tab (as tartrate) : ORAL   | 200   |  |
| 97  | Metronidazole 500 mg tab : ORAL  | 300   |  |
| 98  | Metronidazole 125 mg base / 5 ml (200 mg / 5 ml as benzoate) susp 60 ml : ORAL                                 | 144   |  |
| 99  | Metronidazole 5 mg / ml, 100 ml vl ( IV infusion ) : INJ   | 50    |  |
| 100 | Montelukast 4 mg chewable tablet ( as sodium salt ): ORAL  | 100   |  |
| 101 | Montelukast 5mg chewable tablet ( as sodium salt ) : ORAL  | 100   |  |
| 102 | Montelukast 10 mg tab ( as sodium salt ) : ORAL  | 100   |  |
| 103 | Multivitamin cap : ORAL  | 2,000 |  |
| 104 | Multivitamins / ml drops 15mL: ORAL  | 144   |  |
| 105 | Multivitamin / 5 ml syp60mL : ORAL   | 288   |  |
| 106 | Mupirocin 2 % 15 g : cream   | 150   |  |
| 107 | Naloxone 400 mcg / ml 1 ml amp (im,iv,sc) (as hydrochloride) : INJ   | 10    |  |
| 108 | Nifedipine 10MG cap  | 100   |  |
| 109 | Nystatin 100,000 units / ml susp, 30 ml : ORAL   | 50    |  |
| 110 | Omeprazole 20 mg cap : ORAL  | 3,000 |  |
| 111 | Omeprazole 40 mg cap : ORAL  | 3,000 |  |
| 112 | Omeprazole 40 mg Powder for INJ. Vial +10mL solvent  | 150   |  |
| 113 | Ondansetron 2mg/mL (2mL) amp (IM,IV)   | 100   |  |
| 114 | Oxytocin 10 iu/ml, 1ml Amp (IM,IV)   | 300   |  |
| 115 | Paracetamol 500 mg tab: ORAL   | 3,000 |  |
| 116 | Paracetamol 100 mg / ml drops 15 ml (alcohol free) : ORAL  | 288   |  |
| 117 | Paracetamol 150 mg / 1 ml 2 ml amp : INJ   | 200   |  |
| 118 | Paracetamol 10mg/ml 100mL (IV)   | 100   |  |
| 119 | Paracetamol 125 mg supp : RECTAL   | 50    |  |
| 120 | Paracetamol 250 mg supp : RECTAL   | 100   |  |
| 121 | Penicillin G Benzathine (Benzathine Benzylpenicillin) 1,000.000 units vl (MR) (IM): INJ                        | 10    |  |
| 122 | Penicillin G Benzathine (Benzathine<br>Benzylpenicillin) 1,200.000 units vl (MR)<br>(IM): INJ                  | 10    |  |
| 123 | Phytomenadione (Phytonadione, Vit K1)<br>10 mg / ml 1 ml amp (im,iv,sc) (as                                    | 200   |  |

|     | aqueous coll. soln w/ benzyl alcohol) : INJ   |       |  |
|-----|---|-------|--|
| 124 | Piiperacillin 2g + Tazobactam 250 per vial (as sodium salt)(IV inf) : INJ             | 50    |  |
| 125 | Piiperacillin 4g + Tazobactam 500 per vial (as sodium salt)(IV inf) : INJ             | 50    |  |
| 126 | Potassium Chloride 2 meq / ml 20 ml vl (IV inf) : INJ                                 | 144   |  |
| 127 | Prednisone 5 mg tab : ORAL  | 100   |  |
| 128 | Prednisone 10 mg tab : ORAL   | 100   |  |
| 129 | Prednisone 20 mg tab : ORAL   | 100   |  |
| 130 | Prednisone 10mg/5ml Susp. 60mL  | 72    |  |
| 131 | Purified Rabies Vaccine (Vero Cell) 2.5 I.U and 0.5 mL of solvent                     | 500   |  |
| 132 | Regular Insulin (Recombinant DNA<br>Human) 100 IU/mL, 10mL soln for INJ<br>vial       | 20    |  |
| 133 | Salbutamol 1 mg / ml 2.5 ml (unit dose) (as sulfate): Resp Soln (for nebulization)    | 1500  |  |
| 134 | Salbutamol 2 mg / 5 ml syp 60 ml (as sulfate) : ORAL                                  | 144   |  |
| 135 | Simvastatin 20 mg tab : ORAL  | 500   |  |
| 136 | Simvastatin 40 mg tab : ORAL  | 1000  |  |
| 137 | Sodium Bicarbonate 1 meq / ml 20 ml vl (adult) (IV inf) : INJ                         | 30    |  |
| 138 | Spironolactone 25 mg tab  | 100   |  |
| 139 | Suxamethonium ( succinylcholine ) 20 mg / ml, 10 ml vl ( IV ) (as chloride ) INJ      | 10    |  |
| 140 | Terbutaline 500 mcg / ml 1 ml amp (IV inf) (as sulfate) : INJ                         | 10    |  |
| 141 | Tetanus Immunoglobulin (human) 250 iu/ml, 1 ml prefilled syringe (IM): INJ            | 50    |  |
| 142 | Tramadol 50 mg cap (as hydrochloride) : ORAL  | 300   |  |
| 143 | Tranexamic Acid 100 mg / ml 5 ml amp (im,iv): INJ                                     | 100   |  |
| 144 | 100 mg B1+ 100 mg B6 + 1 mg B12 / 3<br>ml amp m( IV ) : INJ                           | 10    |  |
| 145 | Vitamin B1B6B12 tab   | 5,000 |  |
| 146 | Zinc (Equivalent to 10mg elementalzinc/mL) Drops 15mL, (as Sulfate monohydrate)       | 288   |  |
| 146 | Zinc (Equivalent to 20mg<br>elementalzinc/mL) Syrup 60mL, (as<br>Sulfate monohydrate) | 288   |  |
| 148 | 5 % Dextrose in Lactated Ringer's 1 L bot (IV inf): INJ.                              | 240   |  |
| 149 | 5 % Dextrose in 0.3 % Sodium Chloride<br>500 ml bot ( IV inf ) INJ.                   | 288   |  |
| 150 | 5 % Dextrose in Water 250 ml bot ( IV inf and as which for IV medications ): INJ.     | 100   |  |
| 151 | Glucose ( dextrose ) 50 % 50 ml ( 85 K cal ) vl ( IV ) : INJ.                         | 50    |  |
| 152 | 0.9 % Sodium Chloride 500 ml bot ( IV inf ): INJ.                                     | 480   |  |
| 153 | 0.9 % Sodium Chloride 1 L bot (IV inf): INJ.  | 300   |  |
| 154 | 0.9% Sodium Chloride 1L (Irrigating Solution)   | 120   |  |

| 155 | Lactated Ringer's Solution (Ringer's lactate) 500 ml bot (IV inf): INJ. | 120 |  |
|-----|---|-----|--|
| 156 | Lactated Ringer's Solution (Ringer's lactate) 1 L bot (IV inf): INJ.    | 120 |  |

# Section VII. Technical Specifications Technical Specifications

| Item<br>No. | Description   | Statement of Compliance  |
|-------------|---|--|
|             |   | Bidders must state here either "Comply" or "Not Comply" against each of the individual parameters of each Specification stating the corresponding performance parameter of the equipment offered. Statements of "Comply" or "Not Comply" must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Evidence shall be in the form of manufacturer's un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. A statement either in the Bidder's statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution subject to the applicable laws and issuances.] |
| 1           | Acetylcysteine 600 mg effervescent tab : ORAL   | are appreciable laws and issuances.  |
| 2           | Adenosine 3mg/ml 2ml Amp/Vial   |  |
| 3           | Allopurinol 100 mg tab : ORAL   |  |
| 4           | Aminophylline ( theophylline ethylenediamine ) 25 mg / ml 10 ml amp IV : INJ                  |  |
| 5           | Amiodarone 200 mg tab (as hydrochloride): ORAL  |  |
| 6           | Amiodarone 50 mg / ml, 3 ml amp ( IV ) ( as hydrochloride ): INJ                              |  |
| 7           | Amlodipine 5 mg tab (as besilate): ORAL   |  |
| 8           | Amlodipine 10 mg tab (as besilate): ORAL  |  |
| 9           | Amoxicillin 500 mg cap (as trihydrate): ORAL  |  |
| 10          | Amoxicillin 100 mg / ml granules / powder for drops (suspension) 10 ml (as trihydrate) : ORAL |  |
| 11          | Amoxicillin 250 mg / 5 ml granules / powder for susp 60 ml (as trihydrate) : ORAL             |  |
| 12          | Ampicillin 500 mg vl (im,iv) (as sodium salt): INJ  |  |
| 13          | Ampicillin 500mg Sulbactam250mg (as sodium salt) / vl (im,iv) : INJ                           |  |
| 14          | Anti Rabies Serum (equine) 200 iu ml / 5 ml vl (im) : INJ                                     |  |
| 15          | Anti Tetanus Serum (equine) 1500 iu /0.7 ml 0.7 ml vl / amp (im) : INJ                        |  |
| 16          | Ascorbic Acid (Vit C) 500 mg tab : ORAL   |  |
| 17          | Ascorbic Acid (Vit C) 100 mg / ml drops 15ml : ORAL   |  |
| 18          | Ascorbic Acid (Vit C) 100 mg / 5 ml syr 60 ml : ORAL  |  |
| 19          | Atorvastatin Calcium 20mg Tab   |  |
| 20          | Atracurium (as Besilate) 10mg/mL (2.5mL/5mL) (IV)   |  |
| 21          | Atropine 1 mg / ml 1 ml amp (im,iv) (as sulfate): INJ   |  |
| 22          | Azithromycin 500 mg tab (as base / as dihydrate): ORAL  |  |
| 23          | BCG Vaccine (freeze-dried powder, 100micrograms/0.1 mL, 1mL)                                  |  |

| 24      | Betahistine (as Hydrochloride/dihydrochloride) 16mg,<br>Tablet                                 |
|---------|--|
| 25      | Betahistine (as Hydrochloride/dihydrochloride) 24mg<br>Tablet                                  |
|         | Biphasic Isophane human insulin 70 / 30 (recombinant   |
| 26      | DNA) 70 %isophane susp. 30 % sol. insulin in 100 iu /ml 10mL vl (IM,SC) : INJ                  |
| 27      | Bisacodyl 5 mg tab : ORAL  |
| 28      | Bisacodyl 5 mg (children) supp: RECTAL   |
| 29      | Bisacodyl 10 mg (adult) supp: RECTAL   |
| 20      | Bupivacaine Hydrochloride solution for spinal injection,                                       |
| 30      | 0.5% Heavy, 4 ml amp : Local Anesthetic  |
| 31      | Butamirate 50 mg MR/SRtab (as citrate) : ORAL  |
| 32      | Butorphanol (as Tartrate) 2mg/mL Soln for INJ (IM/IV)  |
| 33      | Calcium Gluconate 10 %, 10 ml amp / vl ( IV ) : INJ  |
| 34      | Carboprost250mcg/ml amp/vial   |
| 35      | Cefalexin 100 mg / ml granules / powder for drops 15 ml  |
| 33      | (as monohydrate): ORAL   |
| 36      | Cefixime 200 mg Tab: ORAL  |
| 37      | Cefixime (as trihydrate ) 20 mg/mL , 10mL drops  |
| 38      | Cefixime (as trihydrate ) 100 mg/5mL , 60mL suspension   |
| 39      | Ceftazidime 500 mg vl (im,iv) ( as pentahydrate ) : INJ  |
| 40      | Ceftazidime 1 g vl (im,iv) ( as pentahydrate ): INJ  |
| 41      | Ceftriaxone 1 g vl 10 ml diluent (iv) (as disodium sodium                                      |
| 71      | salt): INJ   |
| 42      | Cefuroxime 500 mg tab ( as axetil ): ORAL  |
| 43      | Cefuroxime 750 mg vl (im,iv) (as sodium salt): INJ   |
| 44      | Cefuroxime 250 mg / 5 ml granules for susp, 50 ml:   |
| -11     | ORAL   |
| 45      | Cetirizine 2.5 mg / ml syrup (oral drops ) 10mL  |
| 46      | Ciprofloxacin 500mg Tab  |
| 47      | Clarithromycin 500mg tab : ORAL  |
| 48      | Clarithromycin 125 mg / 5 ml granules/powder for susp,   |
|         | 25 ml : ORAL   |
| 49      | Clonidine 75mcg Tab  |
| 50      | Clopidogrel 75 mg tab : ORAL   |
| 51      | Cloxacillin 250 mg / 5 ml powder for syr / susp 60 ml (as                                      |
| <i></i> | sodium salt): ORAL   |
| 52      | Co Amoxiclav Susp 200mg/28.5mg/5ml 70ml  |
| 53      | Co Amoxiclav 457mg/5mL, 70 mL  |
| 54      | Cotrimoxazole (sulfamethoxazole + trimethoprim) 200 mg + 40 mg / 5 ml susp 60 ml : ORAL        |
|         | Diclofenac 25 mg / ml, 3 ml amp ( IM, IV ) ( as sodium   |
| 55      | salt): INJ   |
| 56      | Digoxin 250 mcg (.25 mg) tab : ORAL  |
| 57      | Digoxin 250 mcg / ml 2 ml amp (im,iv): INJ   |
|         | Dobutamine 50 mg / ml ,5mL , 0.5m l solution for   |
| 58      | injection vial: INJ  |
| 59      | Domperidone 10 mg tab : ORAL   |
| 60      | Enoxaparin 40 mg / 0.4 ml prefilled syringe (SC) (as   |
| 00      | sodium):INJ  |
| 61      | Epinephrine (Adrenaline) 1 mg / ml 1 ml amp (im,sc) (as  |
| 62      | hydrochloride): INJ  Erythromycin 500 mg tab (as stearate): OP AI                              |
| 62      | Erythromycin 500 mg tab (as stearate) : ORAL Erythromycin eye ointment 0.5 %, 3.5 g tube : Eye |
| 63      | Ointment 0.5 %, 3.5 g tube : Eye   |
| 64      | Fenofibrate 200mg Cap  |
| L       | 1 Choholate 200mg Cup  |

| ·   |  |
|-----|--|
| 65  | Ferrous Salt 30 mg elemental iron / 5 ml syp 60 ml:  |
|     | ORAL   |
|     | Ferrous Salt tab equivalent to 60 mg elemental iron :  |
| 66  | ORAL N.B. elem iron content of a ferrous salt depends on   |
|     | the type of prep   |
| 67  | Fluconazole 200 mg Cap   |
| 68  | Fluocinonide .05% 5 g tube : CREAM   |
| 69  | Furosemide 10 mg / ml 2 ml amp (im,iv): INJ  |
| 70  | Fusidate Sodium / Fusidic Acid 2 % 5 g tube : CREAM/   |
| 70  | ointment 2% 15g tube   |
|     | Gentamicin 40 mg / ml 1 ml amp / vl (im,iv) (as sulfate0:  |
| 71  | INJ  |
| 72  | Gliclazide 60 mg tab : ORAL  |
|     | Hepatitis B Vaccine (recombinant DNA)  |
| 73  | 10micrograms/0.5mL, 5mL (10dose)   |
|     | Hydralazine 20 mg / ml 1 ml vial (im,iv) (as   |
| 74  | hydrochloride): INJ  |
|     | Hydrocortisone 125 mg / ml 2 ml vial / vl (iv) (as sodium  |
| 75  | succinate): INJ  |
| -   | Hyoscine 20 mg / ml 1 ml amp (im,iv,sc) (as N-   |
| 76  | butylbromide): INJ   |
| 77  | Ibuprofen 200mg Tablet   |
| 78  | Ibuprofen 200mg/5mL 60mL syrup/Suspension  |
| 79  | Insulin Glargine pen   |
|     | 500 mcg Ipratropium (as bromide anhydrous) + 25 mg   |
| 80  | Salbutamol (as base) x 2.5 ml (unit dose) : Resp. Soln (for  |
| 00  | nebulization)  |
| 81  | Isosorbide 5 Mononitrate 60 mg SR tab / cap : ORAL   |
| 82  | Isosorbide Dinitrate 1 mg / ml 10 ml amp (IV) : INJ  |
| 83  | Isosorbide Dinitrate 1 mg / mi 10 mi amp (1 v ) . 11 v<br>Isosorbide Dinitrate 5 mg tab : Sublingual |
| 0.5 | Ketoconazole 20mg/g (2%w/w) 15g cream aluminum   |
| 84  | collapsible tube   |
| 85  | Lactulose 3.3 g / 5 ml (66%) syp 120 ml : ORAL   |
| 86  | Lagundi 600 mg tab: ORAL   |
|     | Vitex Negundo L (Lagundi Leaf) 300 mg / 5 ml syp :   |
| 87  | ORAL 60ML  |
| 88  | Lidocaine 2%, 50mL Soln for INJ vial   |
| 89  | Loratadine 10 mg tab : ORAL  |
| 90  | Losartan 100 mg tab ( as potassium salt ): ORAL  |
| 20  | Magnesium Sulfate 250mg /ml 20 ml amp (im,iv) (as  |
| 91  | heptahydrate): INJ   |
| 02  |  |
| 92  | Mefenamic Acid 500 mg tab/cap: ORAL  Metformin (as hydrochloride) 500mg                              |
| 93  | Methylargametring (Methylarganoving) 200 mag / ml 1 ml   |
| 94  | Methylergometrine (Methylergonovine) 200 mcg / ml 1 ml   |
| 05  | amp (im,iv) (as hydrogen maleate or maleate): INJ  |
| 95  | Metoclopramide 10 mg tab (as hydrochloride): Oral  |
| 96  | Metoprolol 100 mg tab (as tartrate): ORAL  |
| 97  | Metronidazole 500 mg tab : ORAL  |
| 98  | Metronidazole 125 mg base / 5 ml (200 mg / 5 ml as   |
|     | benzoate) susp 60 ml : ORAL  |
| 99  | Metronidazole 5 mg / ml, 100 ml vl (IV infusion): INJ  |
| 100 | Montelukast 4 mg chewable tablet ( as sodium salt ):   |
|     | ORAL   |
| 101 | Montelukast 5mg chewable tablet ( as sodium salt ):  |
|     | ORAL   |
| 102 | Montelukast 10 mg tab ( as sodium salt ): ORAL   |
| 103 | Multivitamin cap : ORAL  |
| 104 | Multivitamins / ml drops 15mL: ORAL  |

| 105 | Multivitamin / 5 ml syp60mL : ORAL   |
|-----|--|
| 106 | Mupirocin 2 % 15 g : cream   |
|     | Naloxone 400 mcg / ml 1 ml amp (im,iv,sc) (as  |
| 107 | hydrochloride): INJ  |
| 108 | Nifedipine 10MG cap  |
| 109 | Nystatin 100,000 units / ml susp, 30 ml : ORAL   |
| 110 | Omeprazole 20 mg cap : ORAL  |
| 111 | Omeprazole 40 mg cap : ORAL  |
| 112 | Omeprazole 40 mg Powder for INJ. Vial +10mL solvent                                      |
| 113 | Ondansetron 2mg/mL (2mL) amp (IM,IV)   |
| 114 | Oxytocin 10 iu/ml, 1ml Amp (IM,IV)   |
| 115 | Paracetamol 500 mg tab: ORAL   |
| 116 | Paracetamol 100 mg / ml drops 15 ml (alcohol free):                                      |
|     | ORAL   |
| 117 | Paracetamol 150 mg / 1 ml 2 ml amp : INJ   |
| 118 | Paracetamol 10mg/ml 100mL (IV)   |
| 119 | Paracetamol 125 mg supp : RECTAL   |
| 120 | Paracetamol 250 mg supp : RECTAL   |
| 121 | Penicillin G Benzathine (Benzathine Benzylpenicillin)                                    |
|     | 1,000.000 units v1 (MR) (IM) : INJ   |
| 122 | Penicillin G Benzathine (Benzathine Benzylpenicillin)                                    |
|     | 1,200.000 units vl (MR) (IM) : INJ Phytomenadione (Phytonadione, Vit K1) 10 mg / ml 1 ml |
| 123 | amp (im,iv,sc) (as aqueous coll. soln w/ benzyl alcohol):                                |
| 123 | INJ  |
|     | Piiperacillin 2g + Tazobactam 250 per vial (as sodium                                    |
| 124 | salt)(IV inf): INJ   |
|     | Piiperacillin 4g + Tazobactam 500 per vial (as sodium                                    |
| 125 | salt)(IV inf): INJ   |
| 126 | Potassium Chloride 2 meq / ml 20 ml vl (IV inf) : INJ                                    |
| 127 | Prednisone 5 mg tab : ORAL   |
| 128 | Prednisone 10 mg tab : ORAL  |
| 129 | Prednisone 20 mg tab : ORAL  |
| 130 | Prednisone 10mg/5ml Susp. 60mL   |
| 131 | Purified Rabies Vaccine (Vero Cell) 2.5 I.U and 0.5 mL of                                |
| 131 | solvent  |
| 132 | Regular Insulin (Recombinant DNA Human) 100 IU/mL,                                       |
|     | 10mL soln for INJ vial   |
| 133 | Salbutamol 1 mg / ml 2.5 ml (unit dose) (as sulfate): Resp                               |
|     | Soln (for nebulization)  |
| 134 | Salbutamol 2 mg / 5 ml syp 60 ml (as sulfate) : ORAL                                     |
| 135 | Simvastatin 20 mg tab : ORAL   |
| 136 | Simvastatin 40 mg tab : ORAL   |
| 137 | Sodium Bicarbonate 1 meq / ml 20 ml vl (adult) (IV inf) :                                |
| 120 | INJ Spironolactone 25 mg tab   |
| 138 |  |
| 139 | Suxamethonium ( succinylcholine ) 20 mg / ml, 10 ml vl ( IV ) (as chloride ) INJ         |
|     | Terbutaline 500 mcg / ml 1 ml amp (IV inf) (as sulfate):                                 |
| 140 | INJ  |
|     | Tetanus Immunoglobulin (human) 250 iu/ml, 1 ml   |
| 141 | prefilled syringe (IM): INJ  |
| 142 | Tramadol 50 mg cap (as hydrochloride) : ORAL   |
| 143 | Tranexamic Acid 100 mg / ml 5 ml amp (im,iv): INJ  |
|     | 100 mg B1+ 100 mg B6 + 1 mg B12 / 3 ml amp m( IV ) :                                     |
| 144 | INJ  |
| 145 | Vitamin B1B6B12 tab  |
|     |  |

| 146  | Zinc (Equivalent to 10mg elementalzinc/mL) Drops 15mL, (as Sulfate monohydrate) |  |
|------|---|--|
| 147  | Zinc (Equivalent to 20mg elementalzinc/mL) Syrup                                |  |
| 1.40 | 60mL, (as Sulfate monohydrate)  |  |
| 148  | 5 % Dextrose in Lactated Ringer's 1 L bot (IV inf): INJ.                        |  |
| 149  | 5 % Dextrose in 0.3 % Sodium Chloride 500 ml bot ( IV inf                       |  |
| 147  | ) INJ.  |  |
| 150  | 5 % Dextrose in Water 250 ml bot ( IV inf and as which for                      |  |
| 130  | IV medications ): INJ.  |  |
| 151  | Glucose (dextrose) 50 % 50 ml (85 K cal) vl (IV): INJ.                          |  |
| 152  | 0.9 % Sodium Chloride 500 ml bot ( IV inf ): INJ.                               |  |
| 153  | 0.9 % Sodium Chloride 1 L bot ( IV inf ): INJ.                                  |  |
| 154  | 0.9% Sodium Chloride 1L (Irrigating Solution)                                   |  |
| 155  | Lactated Ringer's Solution (Ringer's lactate) 500 ml bot (                      |  |
| 133  | IV inf): INJ.   |  |
| 156  | Lactated Ringer's Solution (Ringer's lactate) 1 L bot (IV                       |  |
| 130  | inf): INJ.  |  |

# **BILLS OF QUANTITIES**

# Supply and Delivery of Drugs and Medicines Contract Reference Number: 2024-005

For Goods Offered From Within the Philippines

| Name of Bidder           |  |
|--------------------------|--|
| Invitation to Bid Number |  |

| 1    | 2   | 3                    | 4      |      | 5                               | 6   | 7   | 8  | 9                                     | 10  |
|------|---|----------------------|--------|------|---------------------------------|---|---|--|---------------------------------------|---|
| Item | Description   | Country of<br>Origin | Qty    | Unit | Unit<br>price<br>EXWper<br>item | Transportation<br>and all other<br>costs incidental<br>to delivery, per<br>item | Sales and<br>other taxes<br>payable if<br>Contract is<br>awarded,<br>per item | Cost of<br>Incidental<br>Services, if<br>applicable, per<br>item | Price, per<br>unit<br>(col<br>5+6+7+8 | Total Price<br>delivered Final<br>Destination<br>(col 9) x<br>(col 4) |
| 1    | Acetylcysteine 600 mg effervescent tab: ORAL  |                      | 1,000  |      |                                 |   |   |  |                                       |   |
| 2    | Adenosine 3mg/ml 2ml Amp/Vial   |                      | 10     |      |                                 |   |   |  |                                       |   |
| 3    | Allopurinol 100 mg tab : ORAL   |                      | 500    |      |                                 |   |   |  |                                       |   |
| 4    | Aminophylline (theophylline ethylenediamine) 25 mg / ml 10 ml amp IV : INJ                    |                      | 10     |      |                                 |   |   |  |                                       |   |
| 5    | Amiodarone 200 mg tab (as hydrochloride) : ORAL   |                      | 100    |      |                                 |   |   |  |                                       |   |
| 6    | Amiodarone 50 mg / ml, 3 ml amp ( IV ) ( as hydrochloride ): INJ                              |                      | 10     |      |                                 |   |   |  |                                       |   |
| 7    | Amlodipine 5 mg tab (as besilate): ORAL   |                      | 20,000 |      |                                 |   |   |  |                                       |   |
| 8    | Amlodipine 10 mg tab (as besilate) : ORAL   |                      | 10,000 |      |                                 |   |   |  |                                       |   |
| 9    | Amoxicillin 500 mg cap (as trihydrate) : ORAL   |                      | 3,000  |      |                                 |   |   |  |                                       |   |
| 10   | Amoxicillin 100 mg / ml granules / powder for drops (suspension) 10 ml (as trihydrate) : ORAL |                      | 144    |      |                                 |   |   |  |                                       |   |
| 11   | Amoxicillin 250 mg / 5 ml granules / powder for susp 60 ml (as trihydrate): ORAL              |                      | 144    |      |                                 |   |   |  |                                       |   |
| 12   | Ampicillin 500 mg vl (im,iv) (as sodium salt) : INJ   |                      | 30     |      |                                 |   |   |  |                                       |   |
| 13   | Ampicillin 500mg Sulbactam250mg (as sodium salt) / vl (im,iv) : INJ                           |                      | 200    |      |                                 |   |   |  |                                       |   |

| 14 | Anti Rabies Serum (equine) 200 iu ml / 5 ml vl<br>(im): INJ  | 300   |  |  |  |
|----|--|-------|--|--|--|
| 15 | Anti Tetanus Serum (equine) 1500 iu /0.7 ml<br>0.7 ml vl / amp (im) : INJ  | 2,500 |  |  |  |
| 16 | Ascorbic Acid (Vit C) 500 mg tab : ORAL  | 3,000 |  |  |  |
| 17 | Ascorbic Acid (Vit C) 100 mg / ml drops 15ml<br>: ORAL   | 144   |  |  |  |
| 18 | Ascorbic Acid (Vit C) 100 mg / 5 ml syr 60 ml : ORAL   | 144   |  |  |  |
| 19 | Atorvastatin Calcium 20mg Tab  | 3,000 |  |  |  |
| 20 | Atracurium (as Besilate) 10mg/mL (2.5mL/5mL) (IV)  | 50    |  |  |  |
| 21 | Atropine 1 mg / ml 1 ml amp (im,iv) (as sulfate) : INJ   | 10    |  |  |  |
| 22 | Azithromycin 500 mg tab (as base / as dihydrate) : ORAL  | 3,000 |  |  |  |
| 23 | BCG Vaccine (freeze-dried powder, 100micrograms/0.1 mL, 1mL)   | 100   |  |  |  |
| 24 | Betahistine (as<br>Hydrochloride/dihydrochloride) 16mg, Tablet   | 150   |  |  |  |
| 25 | Betahistine (as<br>Hydrochloride/dihydrochloride) 24mg Tablet  | 300   |  |  |  |
| 26 | Biphasic Isophane human insulin 70 / 30 (recombinant DNA) 70 %isophane susp. 30 % sol. insulin in 100 iu /ml 10mL vl (IM,SC) : INJ | 30    |  |  |  |
| 27 | Bisacodyl 5 mg tab : ORAL  | 100   |  |  |  |
| 28 | Bisacodyl 5 mg (children) supp: RECTAL   | 30    |  |  |  |
| 29 | Bisacodyl 10 mg (adult) supp: RECTAL   | 30    |  |  |  |
| 30 | Bupivacaine Hydrochloride solution for spinal injection, 0.5% Heavy, 4 ml amp : Local Anesthetic                                   | 100   |  |  |  |
| 31 | Butamirate 50 mg MR/SRtab (as citrate): ORAL   | 1,000 |  |  |  |
| 32 | Butorphanol (as Tartrate) 2mg/mL Soln for INJ (IM/IV)  | 70    |  |  |  |
| 33 | Calcium Gluconate 10 %, 10 ml amp / vl ( IV ) : INJ  | 20    |  |  |  |
| 34 | Carboprost250mcg/ml amp/vial   | 10    |  |  |  |
| 35 | Cefalexin 100 mg / ml granules / powder for drops 15 ml (as monohydrate) : ORAL  | 144   |  |  |  |
| 36 | Cefixime 200 mg Tab: ORAL  | 200   |  |  |  |

| 37 | Cefixime (as trihydrate ) 20 mg/mL , 10mL   | 144   |  |      |
|----|---|-------|--|------|
| 38 | drops Cefixime (as trihydrate ) 100 mg/5mL , 60mL                                       | 144   |  |      |
| 39 | suspension Ceftazidime 500 mg vl (im,iv) ( as   | 30    |  |      |
| 40 | pentahydrate ) : INJ Ceftazidime 1 g vl (im,iv) ( as pentahydrate ) :                   | 30    |  |      |
| 41 | INJ Ceftriaxone 1 g vl 10 ml diluent (iv) (as   | 200   |  |      |
| 42 | disodium sodium salt): INJ Cefuroxime 500 mg tab ( as axetil ): ORAL                    | 2,000 |  |      |
| 43 | Cefuroxime 750 mg vl (im,iv) (as sodium salt): INJ                                      | 50    |  |      |
| 44 | Cefuroxime 250 mg / 5 ml granules for susp,<br>50 ml : ORAL                             | 288   |  |      |
| 45 | Cetirizine 2.5 mg / ml syrup (oral drops )<br>10mL                                      | 144   |  |      |
| 46 | Ciprofloxacin 500mg Tab   | 500   |  |      |
| 47 | Clarithromycin 500mg tab: ORAL  | 500   |  |      |
| 48 | Clarithromycin 125 mg / 5 ml<br>granules/powder for susp, 25 ml : ORAL                  | 144   |  |      |
| 49 | Clonidine 75mcg Tab   | 400   |  |      |
| 50 | Clopidogrel 75 mg tab : ORAL  | 1,500 |  |      |
| 51 | Cloxacillin 250 mg / 5 ml powder for syr / susp 60 ml (as sodium salt) : ORAL           | 144   |  |      |
| 52 | Co Amoxiclav Susp 200mg/28.5mg/5ml 70ml   | 288   |  |      |
| 53 | Co Amoxiclav 457mg/5mL, 70 mL   | 288   |  |      |
| 54 | Cotrimoxazole (sulfamethoxazole + trimethoprim) 200 mg + 40 mg / 5 ml susp 60 ml : ORAL | 72    |  |      |
| 55 | Diclofenac 25 mg / ml, 3 ml amp ( IM, IV ) ( as sodium salt ): INJ                      | 10    |  |      |
| 56 | Digoxin 250 mcg (.25 mg) tab : ORAL   | 100   |  |      |
| 57 | Digoxin 250 mcg / ml 2 ml amp (im,iv) : INJ   | 20    |  |      |
| 58 | Dobutamine 50 mg / ml ,5mL , 0.5m l solution for injection vial : INJ                   | 10    |  |      |
| 59 | Domperidone 10 mg tab : ORAL  | 100   |  |      |
| 60 | Enoxaparin 40 mg / 0.4 ml prefilled syringe (SC) (as sodium):INJ                        | 30    |  |      |
| 61 | Epinephrine (Adrenaline) 1 mg / ml 1 ml amp (im,sc) (as hydrochloride) : INJ            | 50    |  |      |
|    | Erythromycin 500 mg tab (as stearate): ORAL   | 300   |  | <br> |

| 63 | Erythromycin eye ointment 0.5 %, 3.5 g tube :<br>Eye Ointment   | 30    |  |  |  |
|----|---|-------|--|--|--|
| 64 | Fenofibrate 200mg Cap   | 300   |  |  |  |
| 65 | Ferrous Salt 30 mg elemental iron / 5 ml syp<br>60 ml : ORAL  | 144   |  |  |  |
| 66 | Ferrous Salt tab equivalent to 60 mg elemental iron: ORAL N.B. elem iron content of a ferrous salt depends on the type of prep    | 3000  |  |  |  |
| 67 | Fluconazole 200 mg Cap  | 100   |  |  |  |
| 68 | Fluocinonide .05% 5 g tube : CREAM  | 100   |  |  |  |
| 69 | Furosemide 10 mg / ml 2 ml amp (im,iv): INJ   | 200   |  |  |  |
| 70 | Fusidate Sodium / Fusidic Acid 2 % 5 g tube : CREAM/ ointment 2% 15g tube   | 50    |  |  |  |
| 71 | Gentamicin 40 mg / ml 1 ml amp / vl (im,iv) (as sulfate0 : INJ  | 30    |  |  |  |
| 72 | Gliclazide 60 mg tab : ORAL   | 3,000 |  |  |  |
| 73 | Hepatitis B Vaccine (recombinant DNA)<br>10micrograms/0.5mL, 5mL (10dose)   | 20    |  |  |  |
| 74 | Hydralazine 20 mg / ml 1 ml vial (im,iv) (as hydrochloride) : INJ   | 20    |  |  |  |
| 75 | Hydrocortisone 125 mg / ml 2 ml vial / vl (iv) (as sodium succinate) : INJ  | 100   |  |  |  |
| 76 | Hyoscine 20 mg / ml 1 ml amp (im,iv,sc) (as N-butylbromide) : INJ   | 200   |  |  |  |
| 77 | Ibuprofen 200mg Tablet  | 200   |  |  |  |
| 78 | Ibuprofen 200mg/5mL 60mL syrup/Suspension   | 144   |  |  |  |
| 79 | Insulin Glargine pen  | 50    |  |  |  |
| 80 | 500 mcg Ipratropium (as bromide anhydrous)<br>+ 25 mg Salbutamol (as base) x 2.5 ml (unit<br>dose): Resp. Soln (for nebulization) | 1,000 |  |  |  |
| 81 | Isosorbide 5 Mononitrate 60 mg SR tab / cap : ORAL  | 1,000 |  |  |  |
| 82 | Isosorbide Dinitrate 1 mg / ml 10 ml amp (IV)<br>: INJ  | 100   |  |  |  |
| 83 | Isosorbide Dinitrate 5 mg tab : Sublingual  | 500   |  |  |  |
| 84 | Ketoconazole 20mg/g (2%w/w) 15g cream aluminum collapsible tube   | 100   |  |  |  |
| 85 | Lactulose 3.3 g / 5 ml (66%) syp 120 ml :<br>ORAL   | 144   |  |  |  |
| 86 | Lagundi 600 mg tab : ORAL   | 1,000 |  |  |  |

| 87  | Vitex Negundo L (Lagundi Leaf) 300 mg / 5<br>ml syp: ORAL 60ML  | 288   |  |  |
|-----|---|-------|--|--|
| 88  | Lidocaine 2%, 50mL Soln for INJ vial  | 50    |  |  |
| 89  | Loratadine 10 mg tab : ORAL   | 500   |  |  |
| 90  | Losartan 100 mg tab ( as potassium salt ): ORAL   | 3,000 |  |  |
| 91  | Magnesium Sulfate 250mg /ml 20 ml amp<br>(im,iv) (as heptahydrate) : INJ                                  | 50    |  |  |
| 92  | Mefenamic Acid 500 mg tab/cap : ORAL  | 1,500 |  |  |
| 93  | Metformin (as hydrochloride) 500mg  | ,5000 |  |  |
| 94  | Methylergometrine (Methylergonovine) 200 mcg / ml 1 ml amp (im,iv) (as hydrogen maleate or maleate) : INJ | 50    |  |  |
| 95  | Metoclopramide 10 mg tab (as hydrochloride) :<br>Oral   | 300   |  |  |
| 96  | Metoprolol 100 mg tab (as tartrate): ORAL   | 200   |  |  |
| 97  | Metronidazole 500 mg tab : ORAL   | 300   |  |  |
| 98  | Metronidazole 125 mg base / 5 ml (200 mg / 5 ml as benzoate) susp 60 ml : ORAL                            | 144   |  |  |
| 99  | Metronidazole 5 mg / ml, 100 ml vl ( IV infusion ): INJ   | 50    |  |  |
| 100 | Montelukast 4 mg chewable tablet ( as sodium salt ): ORAL   | 100   |  |  |
| 101 | Montelukast 5mg chewable tablet ( as sodium salt ): ORAL  | 100   |  |  |
| 102 | Montelukast 10 mg tab ( as sodium salt ): ORAL  | 100   |  |  |
| 103 | Multivitamin cap : ORAL   | 2,000 |  |  |
| 104 | Multivitamins / ml drops 15mL: ORAL   | 144   |  |  |
| 105 | Multivitamin / 5 ml syp60mL : ORAL  | 288   |  |  |
| 106 | Mupirocin 2 % 15 g : cream  | 150   |  |  |
| 107 | Naloxone 400 mcg / ml 1 ml amp (im,iv,sc)<br>(as hydrochloride) : INJ                                     | 10    |  |  |
| 108 | Nifedipine 10MG cap   | 100   |  |  |
| 109 | Nystatin 100,000 units / ml susp, 30 ml : ORAL  | 50    |  |  |
| 110 | Omeprazole 20 mg cap : ORAL   | 3,000 |  |  |
| 111 | Omeprazole 40 mg cap : ORAL   | 3,000 |  |  |
| 112 | Omeprazole 40 mg Powder for INJ. Vial<br>+10mL solvent  | 150   |  |  |
| 113 | Ondansetron 2mg/mL (2mL) amp (IM,IV)  | 100   |  |  |
| 114 | Oxytocin 10 iu/ml, 1ml Amp (IM,IV)  | 300   |  |  |

| 115 | Paracetamol 500 mg tab: ORAL   | 3,000 |  |  |  |
|-----|--|-------|--|--|--|
| 116 | Paracetamol 100 mg / ml drops 15 ml (alcohol free): ORAL   | 288   |  |  |  |
| 117 | Paracetamol 150 mg / 1 ml 2 ml amp : INJ   | 200   |  |  |  |
| 118 | Paracetamol 10mg/ml 100mL (IV)   | 100   |  |  |  |
| 119 | Paracetamol 125 mg supp : RECTAL   | 50    |  |  |  |
| 120 | Paracetamol 250 mg supp: RECTAL  | 100   |  |  |  |
| 121 | Penicillin G Benzathine (Benzathine<br>Benzylpenicillin) 1,000.000 units vl (MR) (IM)<br>: INJ                       | 10    |  |  |  |
| 122 | Penicillin G Benzathine (Benzathine<br>Benzylpenicillin) 1,200.000 units vl (MR) (IM)<br>: INJ                       | 10    |  |  |  |
| 123 | Phytomenadione (Phytonadione, Vit K1) 10 mg / ml 1 ml amp (im, iv, sc) (as aqueous coll. soln w/benzyl alcohol): INJ | 200   |  |  |  |
| 124 | Piiperacillin 2g + Tazobactam 250 per vial (as sodium salt)(IV inf) : INJ  | 50    |  |  |  |
| 125 | Piiperacillin 4g + Tazobactam 500 per vial (as sodium salt)(IV inf) : INJ  | 50    |  |  |  |
| 126 | Potassium Chloride 2 meq / ml 20 ml vl (IV inf): INJ   | 144   |  |  |  |
| 127 | Prednisone 5 mg tab : ORAL   | 100   |  |  |  |
| 128 | Prednisone 10 mg tab : ORAL  | 100   |  |  |  |
| 129 | Prednisone 20 mg tab : ORAL  | 100   |  |  |  |
| 130 | Prednisone 10mg/5ml Susp. 60mL   | 72    |  |  |  |
| 131 | Purified Rabies Vaccine (Vero Cell) 2.5 I.U and 0.5 mL of solvent  | 500   |  |  |  |
| 132 | Regular Insulin (Recombinant DNA Human)<br>100 IU/mL, 10mL soln for INJ vial   | 20    |  |  |  |
| 133 | Salbutamol 1 mg / ml 2.5 ml (unit dose) (as sulfate) : Resp Soln (for nebulization)                                  | 1500  |  |  |  |
| 134 | Salbutamol 2 mg / 5 ml syp 60 ml (as sulfate) : ORAL   | 144   |  |  |  |
| 135 | Simvastatin 20 mg tab : ORAL   | 500   |  |  |  |
| 136 | Simvastatin 40 mg tab : ORAL   | 1000  |  |  |  |
| 137 | Sodium Bicarbonate 1 meq / ml 20 ml vl (adult) (IV inf): INJ   | 30    |  |  |  |
| 138 | Spironolactone 25 mg tab   | 100   |  |  |  |
| 139 | Suxamethonium ( succinylcholine ) 20 mg / ml, 10 ml vl ( IV ) (as chloride ) INJ                                     | 10    |  |  |  |

| 140 | Terbutaline 500 mcg / ml 1 ml amp (IV inf) (as sulfate): INJ                       | 10    |  |
|-----|--|-------|--|
| 141 | Tetanus Immunoglobulin (human) 250 iu/ml,<br>1 ml prefilled syringe (IM) : INJ     | 50    |  |
| 142 | Tramadol 50 mg cap (as hydrochloride) : ORAL                                       | 300   |  |
| 143 | Tranexamic Acid 100 mg / ml 5 ml amp (im,iv): INJ                                  | 100   |  |
| 144 | 100 mg B1+ 100 mg B6 + 1 mg B12 / 3 ml<br>amp m( IV ) : INJ                        | 10    |  |
| 145 | Vitamin B1B6B12 tab  | 5,000 |  |
| 146 | Zinc (Equivalent to 10mg elementalzinc/mL) Drops 15mL, (as Sulfate monohydrate)    | 288   |  |
| 147 | Zinc (Equivalent to 20mg elementalzinc/mL)<br>Syrup 60mL, (as Sulfate monohydrate) | 288   |  |
| 148 | 5 % Dextrose in Lactated Ringer's 1 L bot ( IV inf ): INJ.                         | 240   |  |
| 149 | 5 % Dextrose in 0.3 % Sodium Chloride 500 ml bot ( IV inf ) INJ.                   | 288   |  |
| 150 | 5 % Dextrose in Water 250 ml bot ( IV inf and as which for IV medications ): INJ.  | 100   |  |
| 151 | Glucose ( dextrose ) 50 % 50 ml ( 85 K cal ) vl ( IV ) : INJ.                      | 50    |  |
| 152 | 0.9 % Sodium Chloride 500 ml bot ( IV inf ): INJ.                                  | 480   |  |
| 153 | 0.9 % Sodium Chloride 1 L bot ( IV inf ): INJ.                                     | 300   |  |
| 154 | 0.9% Sodium Chloride 1L (Irrigating Solution)                                      | 120   |  |
| 155 | Lactated Ringer's Solution (Ringer's lactate) 500 ml bot (IV inf): INJ.            | 120   |  |
| 156 | Lactated Ringer's Solution (Ringer's lactate) 1<br>L bot (IV inf): INJ.            | 120   |  |
|     | TOTAL AMOUNT IN WORDS:   |       |  |

#### SUBMITTED BY:

| NAME AND SIGNATURE |  |
|--------------------|--|
| POSITION           |  |
| NAME OF COMPANY    |  |
| DATE               |  |

# Section VIII. Checklist of Technical and Financial Documents

(Goods and Services: Medicines and Medical Supplies)

# I. Technical Component Envelope

| Le | gal Do        | <u>ocuments</u>   |
|----|---------------|---|
|    | (a)           | Valid PhilGEPS Registration Certificate (Platinum Membership) (all pages) in accordance with Section 8.5.2 of the IRR;  |
| Te | <u>chnica</u> | al Documents  |
|    | (b)           | Statement of the prospective bidder of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid; <u>and</u>   |
|    | (c)           | Statement of the bidder's Single Largest Completed Contract (SLCC) similar to the contract to be bid, except under conditions provided for in Sections 23.4.1.3 and 23.4.2.4 of the 2016 revised IRR of RA No. 9184, within the relevant period as provided in the Bidding Documents; and   |
|    | (d)           | Original copy of Bid Security. If in the form of a Surety Bond, submit also a certification issued by the Insurance Commission or Original copy of Notarized Bid Securing Declaration; and  |
|    | (e)           | Conformity with the Technical Specifications, which may include production/delivery schedule, manpower requirements, and/or after-sales/parts, if applicable; and   |
|    | (f)           | Original duly signed Omnibus Sworn Statement (OSS) <u>and</u> if applicable, Original Notarized Secretary's Certificate in case of a corporation, partnership, or cooperative; or Original Special Power of Attorney of all members of the joint venture giving full power and authority to its officer to sign the OSS and do acts to represent the Bidder; <u>and</u> |
|    | (g)           | License to Operate (LTO); and   |
|    | (h)           | Certificate of Product Registration (CPR); and  |
|    | (i)           | ID of Pharmacist; and   |
|    | (j)           | Certificate of Good Manufacturing Practice (CGMP).  |

| Financial 1 | Documents |
|-------------|-----------|
|-------------|-----------|

☐ (k) The prospective bidder's computation of Net Financial Contracting Capacity (NFCC) or a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation.

#### Class "B" Documents

[] (1) If applicable, a duly signed joint venture agreement (JVA) in case the joint venture is already in existence or duly notarized statements from all the potential joint venture partners stating that they will enter into and abide by the provisions of the JVA in the instance that the bid is successful.

Note: Any missing documents in the above-mentioned checklist is a ground for outright rejection of the bid.

## II. Financial Component Envelope

□ (m) Original of duly signed and accomplished Financial Bid Form; and
 □ (n) Original of duly signed and accomplished Price Schedule(s).

### Other Documentary Requirements Under R.A. 9184 (As Applicable)

- ☐ (o) [For foreign bidders claiming by reason of their country's extension of reciprocal rights to Filipinos] Certification from the relevant government office of their country stating that Filipinos are allowed to participate in government procurement activities for the same item or product.
- ☐ (p) Certification from the DTI if the Bidder claims preference as a Domestic Bidder or Domestic Entity.

## **FORMS**

## Bid Form for the Procurement of Goods

| Dat   | e:   |
|---|--|
| Project/Contract Identification No.:  |  |
| Co: CITY GOVERNMENT OF NAGA City Hall Compound, J. Miranda Avenue Concepcion Pequena, Naga City   |  |
| Having examined the Philippine Bidding Docum Supplemental or Bid Bulletin Numbers [insert not be reby duly acknowledged, we, the understand the property of the propert | imbers], the receipt of which is   |
| [supply/deliver/perform] [description of the Goods]in conformity with the   | e said PBDs for the sum of   |
| Pesos [total Bid amount in words and figures] or the valuated and corrected for computational errors, and eccordance with the Price Schedules attached herewith and total bid price includes the cost of all taxes, such as, but pplicable taxes, e.g. (i) value added tax (VAT), (ii) income other fiscal levies and duties], which are itemized herein or in  | other bid modifications in<br>made part of this Bid. The<br>not limited to: [specify the<br>tax, (iii) local taxes, and (iv) |
| If our Bid is accepted, we undertake:  a. to deliver the goods in accordance with the d the Schedule of Requirements of the Phili (PBDs);   | · -  |
| b. to provide a performance security in the forr times prescribed in the PBDs;  | m, amounts, and within the   |
| c. to abide by the Bid Validity Period specified in binding upon us at any time before the expirate   |  |
| [Insert this paragraph if Foreign-Assisted Project with the Development Partner: Commissions or gratuities, if any, paid or to be paid b Bid, and to contract execution if we are awarded the contract Name and address Amount and Purpose of Of agent Currency Commission or gratuity  | y us to agents relating to this  |
| if none, state "None") ]  |  |

Until a formal Contract is prepared and executed, this Bid, together with your written acceptance thereof and your Notice of Award, shall be binding upon us.

| We understand that you are not bound to accept the Lowest Calculated Bid or any Bid you may receive.   |  |  |  |  |
|--|--|--|--|--|
| We certify/confirm that we comply with the eligibility requirements pursuant to the PBDs.  |  |  |  |  |
| The undersigned is authorized to submit the bid on behalf of [name of the bidder] as evidenced by the attached [state the written authority].                        |  |  |  |  |
| We acknowledge that failure to sign each and every page of this Bid Form, including the attached Schedule of Prices, shall be a ground for the rejection of our bid. |  |  |  |  |
| Name:  |  |  |  |  |
| Legal capacity:  |  |  |  |  |
| Signature:   |  |  |  |  |
| Duly authorized to sign the Bid for and behalf of:   |  |  |  |  |
| Date:  |  |  |  |  |

# **Omnibus Sworn Statement**

REPUBLIC OF THE PHILIPPINES) CITY OF NAGA ) S.S.

|                       | AFFIDAVIT  |
|-----------------------|--|
| Ι,                    | ,  |
| <sup>[Na</sup><br>aft | er having been duly sworn in accordance with law, do hereby depose and state that:   |
| 1.                    | [If a sole proprietorship:] I am the sole proprietor or authorized representative of with office address at  |
|                       | ;  |
|                       | [If a partnership, corporation, cooperative, or joint venture:] $I$ am the duly authorized and designated representative of with   |
|                       | office address at;   |
| 2.                    | [If a sole proprietorship:] As the owner and sole proprietor, or authorized representative of  |
|                       | to sign and execute the ensuing contract for   |
|                       | shown in the attached duly notarized Special Power of Attorney;  |
|                       | [If a partnership, corporation, cooperative, or joint venture:] I am granted full power and authority to do execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for of the City Government of Naga, as shown in the attached [state title of attached document showing proof of authorization (e.g., duly notarized Secretary's Certificate, Board/Partnership Resolution, or Special Power of Attorney, whichever is applicable;)]; |
| 3.                    | is not "blacklisted" or barred from bidding by the Government of the Philippines or any of its agencies, offices, corporations, or Local Government Units, foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the Government Procurement Policy Board, by itself or by relation, membership, association, affiliation, or controlling interest with another blacklisted person or  |
|                       | entity as defined and provided for in the Uniform Guidelines on Blacklisting;  |
| 4.                    | Each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;  |
| 5.                    | is authorizing the Head of the   |
| ٠.                    | Procuring Entity or its duly authorized representative(s) to verify all the documents submitted:   |

| 6. | [If a sole proprietorship:] The owner or sole proprietor is not related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree; |  |  |  |  |  |  |
|----|---|--|--|--|--|--|--|
|    | [If a partnership or cooperative:]None of the officers and members of is related to the Head of the Procuring Entity,   |  |  |  |  |  |  |
|    | members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;  |  |  |  |  |  |  |
|    | [If a corporation or joint venture:] None of the officers, directors, and controlling stockholders of  is related to the Head of the Procuring Entity,  |  |  |  |  |  |  |
|    | members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;  |  |  |  |  |  |  |
| 7. | complies with existing labor laws and standards; and  |  |  |  |  |  |  |
| 8. | is aware of and has undertaken the responsibilities as a Bidder in compliance with the Philippine Bidding Documents, which includes:  |  |  |  |  |  |  |
|    | <ul><li>a. Carefully examining all of the Bidding Documents;</li><li>b. Acknowledging all conditions, local or otherwise, affecting the implementation of the Contract;</li></ul>   |  |  |  |  |  |  |
|    | c. Making an estimate of the facilities available and needed for the contract to be bid, if any; and  |  |  |  |  |  |  |
|    | d. Inquiring or securing Supplemental/Bid Bulletin(s) issued for the  |  |  |  |  |  |  |
| 9. | did not give or pay directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.   |  |  |  |  |  |  |
| 10 | In case advance payment was made or given, failure to perform or deliver any of the obligations and undertakings in the contract shall be sufficient grounds to constitute criminal liability for Swindling (Estafa) or the commission of fraud with unfaithfulness or abuse of confidence through misappropriating or converting any                                     |  |  |  |  |  |  |
|    | payment received by a person or entity under an obligation involving the duty to deliver certain goods or services, to the prejudice of the public and the government of the Philippines pursuant to Article 315 of Act No. 3815 s. 1930, as amended, or  |  |  |  |  |  |  |
|    | the Revised Penal Code.   |  |  |  |  |  |  |

|  | Name of Bidder or   |                           |                    |
|--|---------------------|---------------------------|--------------------|
|  | Name of Bidder or   |                           |                    |
|  | Name of Bidder or i |                           |                    |
|  | Name of Bidder or i |                           |                    |
|  | name of bluder of t | ts Authorize              | ed Representative  |
|  |                     | y's legal capa<br>Affiant | acity              |
|  |                     | Amam                      |                    |
| CLIECORIED AND CWORN to be for an add  | 1.:- 4              |                           | 20                 |
| SUBSCRIBED AND SWORN to before me the place of execution], Philippines. Affiant tentified by me through competent evidence of identified by me through competent evidence. | t/s is/are persona  | ally know                 | n to me and was/we |
| A.M. No. 02-8-13-SC). Affiant/s exhibited to me entification card used], with his/her photograph and signature   |                     |                           |                    |
| ommunity Tax Certificate Noissued on   | e appearing there   | on, with h<br>at          | o and ms/ n        |
| Witness my hand and seal this day of   |                     | _, 20                     | [month] [year].    |
| , ,  |                     | ,                         |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |
|  |                     |                           |                    |

#### **BID SECURING DECLARATION**

| Project/0 | Contract | Identification | No.: |  |
|-----------|----------|----------------|------|--|
|           |          |                |      |  |

#### To: **CITY GOVERNMENT OF NAGA**

City Hall Compound, J. Miranda Avenue Concepcion Pequena, Naga City

I/We, the undersigned, declare that:

- 1. I/We understand that, according to your conditions, bids must be supported by a Bid Security, which may be in the form of a Bid Securing Declaration.
- 2. I/We accept that: (a) I/we will be automatically disqualified from bidding for any procurement contract with any procuring entity for a period of two (2) years upon receipt of your Blacklisting Order; and, (b) I/we will pay the applicable fine provided under Section 6 of the Guidelines on the Use of Bid Securing Declaration, within fifteen (15) days from receipt of the written demand by the procuring entity for the commission of acts resulting to the enforcement of the bid securing declaration under Sections 23.1(b), 34.2, 40.1 and 69.1, except 69.1(f),of the IRR of RA No. 9184; without prejudice to other legal action the government may undertake.
- 3. I/We understand that this Bid Securing Declaration shall cease to be valid on the following circumstances:
  - a. Upon expiration of the bid validity period, or any extension thereof pursuant to your request;
  - b. I am/we are declared ineligible or post-disqualified upon receipt of your notice to such effect, and (i) I/we failed to timely file a request for reconsideration or (ii) I/we filed a waiver to avail of said right; and
  - c. I am/we are declared the bidder with the Lowest Calculated Responsive Bid, and I/we have furnished the performance security and signed the Contract.

| IN WITN | ESS WHEREOF, | I/We have hereunto set r | ny/our hand/s this                  | _ day                 |  |
|---------|--------------|--------------------------|-------------------------------------|-----------------------|--|
|         | [month],     | [year] at                | [place of execution].               | [place of execution]. |  |
|         |              |                          |                                     |                       |  |
|         |              |                          |                                     |                       |  |
|         |              |                          |                                     |                       |  |
|         |              | Name of Bidd             | er or its Authorized Representative |                       |  |
|         |              |                          |                                     |                       |  |
|         |              | Sig                      | natory's legal capacity             |                       |  |

Affiant

| SUBSCRIBED AND SWORN t                             | o before me this   | day of                | , 20       | [month] [year] <b>at</b> |
|--|--------------------|-----------------------|------------|--------------------------|
| [place of execution],Philipp                       | pines. Affiant/s   | is/are personally kn  | own to me  | and was/were             |
| identified by me through competent evide           | ence of identity a | s defined in the 2004 | Rules on N | otarial Practice         |
| (A.M. No. 02-8-13-SC). Affiant/s exhi              | bited to me his    | /her                  | [insert    | type of government       |
| identification card used], with his/her photograp! |                    |                       |            |                          |
| Community Tax Certificate No                       | issued on          | at                    |            | ·                        |
|  |                    |                       |            |                          |
| Witness my hand and seal this                      | day of             | . 20                  | [month] [  | vearl.                   |

# STATEMENT OF THE BIDDER'S SINGLE LARGEST COMPLETED CONTRACT (SLCC)

(similar to the contract to be bid, except under conditions provided for in Section 23.4.1.3 and 23.4.2.4 of the IRR, within 10 years)

| Business Name:<br>Business Address: |                     |                      |                                |                   |                          |  |                     |
|-------------------------------------|---------------------|----------------------|--------------------------------|-------------------|--------------------------|--|---------------------|
| Name of Contract                    | Date of<br>Contract | Contract<br>Duration | Owner's<br>Name and<br>Address | Kinds of<br>Goods | Amount<br>of<br>Contract | Amount of Completed contract (amount of completed contracts, adjusted by the Bidder to current prices using PSA's consumer price index, if necessary for the purpose of meeting the SLCC requirement | Date of<br>Delivery |
| GOVERNMENT                          |                     |                      |                                |                   |                          |  |                     |
|                                     |                     |                      |                                |                   |                          |  |                     |
|                                     |                     |                      |                                |                   |                          |  |                     |
|                                     |                     |                      |                                |                   |                          |  |                     |
| PRIVATE                             |                     |                      |                                |                   |                          |  |                     |
|                                     | ſ                   | l                    |                                | 1                 | 1                        |  |                     |

Note: This statement shall be supported with: 1. Contract, 2. Certificate of Completion, 3. End user's acceptance or official receipt(s) or sales invoice issued for the contract

# STATEMENT OF ALL ONGOING GOVERNMENT AND PRIVATE CONTRACTS

(including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid) **Business Name:** Business Address: Value of Date of Owner's Name Kinds of Deliverv Contract Amount of Name of Contract Outstanding Schedule Contract Duration and Address Goods Contract Contracts GOVERNMENT PRIVATE Note: This statement shall be supported with: 1. Notice of Award and/or Contract; 2. Notice to Proceed, 3. Certificate of Accomplishment signed by the owner or authorized representative Submitted by: Name & Signature of Authorized Representative

Designation

Date

#### Note:

- PLEASE USE THE FORMS PROVIDED IN THIS PBD AND SHOULD REMAIN UNALTERED.
- KINDLY PUT TABS AT THE RIGHT SIDE OF ALL THE DOCUMENTARY REQUIREMENTS.



